

A Systematic Review of the Anticancer Properties of Compounds Isolated from Licorice (Gancao)

Authors

Zheng-Hai Tang¹, Ting Li¹, Yun-Guang Tong², Xiao-Jia Chen¹, Xiu-Ping Chen¹, Yi-Tao Wang¹, Jin-Jian Lu¹

Affiliations

¹ State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China

² Department of Medicine, Cedars-Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, CA, USA

Key words

- *Glycyrrhiza glabra*
- Leguminosae
- licorice
- anticancer
- mechanism
- triterpenoids
- flavonoids

received April 28, 2015
revised August 14, 2015
accepted October 16, 2015

Bibliography

DOI <http://dx.doi.org/10.1055/s-0035-1558227>
Planta Med 2015; 81:
1670–1687 © Georg Thieme
Verlag KG Stuttgart · New York ·
ISSN 0032-0943

Correspondence

Dr. Jin-jian Lu
State Key Laboratory of Quality
Research in Chinese Medicine
Institute of Chinese Medical
Sciences
University of Macau
Avenida da Universidade
Taipa, Macao 999078
China
Phone: + 85 3 88 22 46 74
Fax: + 85 3 28 84 13 58
jinjianlu@umac.mo

Abstract



Licorice (Gancao in Chinese) has been used worldwide as a botanical source in medicine and as a sweetening agent in food products for thousands of years. Triterpene saponins and flavonoids are its main ingredients that exhibit a variety of biological activities, including hepatoprotective, antiulcer, anti-inflammatory, antiviral and anticancer effects among others. This review attempts to summarize the current knowledge on the anticancer properties and mechanisms of the compounds isolated from licorice and obtain new insights for further research and development of licorice. A broad spectrum of *in vitro* and *in vivo* studies have recently demonstrated that the mixed extracts and purified compounds from licorice exhibit evident anticancer properties by inhibition of proliferation, induction of cell cycle arrest, apoptosis, autophagy, differentiation, suppression of metastasis, angiogenesis, and sensitization of chemotherapy or radiotherapy. A combined treatment of licorice compounds and clinical chemotherapy drugs remarkably enhances anticancer effects and reduces the side effects of chemotherapeutics. Furthermore, glycyrrhizic acid and glycyrrhetic acid in licorice have been indicated to present obvious liver-targeting effects in targeted drug delivery systems for hepatocellular carcinoma treatment.

Abbreviations



20-HETE: 20-hydroxyeicosatetraenoic acid
70% EEL: 70% ethanol (volume, CH₃CH₂OH:
H₂O = 70 : 30) extracts of licorice
70% MEL: 70% methanol (volume, CH₃OH:
H₂O = 70 : 30) extracts of licorice
80% EEL: 80% ethanol (volume, CH₃CH₂OH:
H₂O = 80 : 20) extracts of licorice
AOM: azoxymethane

AP-1: activator protein 1
β-hydroxy-DHP: 1-(2,4-dihydroxyphenyl)-3-hydroxy-3-(4'-hydroxyphenyl) 1-propanone
CDK: cyclin-dependent kinase
COX-2: cyclooxygenases-2
CP: cyclophosphamide
CYP19: cytochrome P450 19
DMBA: dimethylbenz[a]anthracene
DR4: death receptor 4
DSS: dextran sulfate sodium
EAT: Ehrlich ascites tumor
ER: endoplasmic reticulum
ERK: extracellular regulated protein kinases
FasL: Fas ligand
GA: glycyrrhetic acid
GBD: glabridin
GL: glycyrrhizic acid
GLY: glycyrol
GSH: glutathione hormone
HCC: hepatocellular carcinoma
HEEL: hexane/ethanol extraction of licorice
HMGB1: high-mobility group box 1
HUVECs: human umbilical vein endothelial cells
i. g.: intragastric administration
i. m.: intramuscular injection
i. p.: intraperitoneal injection
i. t.: intratumor injection
i. v.: intravenous injection
IAA: isoangustone A
ICAM: intercellular adhesion molecule
IL: interleukin
ISLG: isoliquiritigenin
ISLT: isoliquiritin
JNK: c-Jun N-terminal kinase
LCA: licochalcone A
LCB: licochalcone B
LCE: licochalcone E
LCM: licocoumarone
LG: liquiritigenin
LRD: licoricidin
LT: liquiritin

MMP:	mitochondrial membrane potential	PKC:	protein kinase C
MMP-2:	matrix metalloproteinase-2	ROS:	reactive oxygen species
MMP-9:	matrix metalloproteinase-9	s.c.:	subcutaneous injection
mTOR:	mammalian target of rapamycin	STAT3:	signal transducer and activator of transcription 3
MVD:	microvessel density	TCM:	traditional Chinese medicine
NAT:	N-acetyltransferase	TDDS:	target drug delivery systems
NF- κ B:	nuclear factor- κ B	TNF- α :	tumor necrosis factor- α
NSCLC:	non small cell lung carcinoma	Top I:	topoisomerase I
ODC:	ornithine decarboxylase	TPA:	12-O-tetradecanoylphorbol 13-acetate
p.o.:	<i>per os</i>	uPA:	urokinase-type plasminogen activator
PARP:	poly(ADP-ribose)-polymerase	UVB:	ultraviolet radiation b
PCNA:	proliferative cell nuclear antigen	VCAM:	vascular cell adhesion molecule
PGE ₂ :	prostaglandin E ₂	VEGF:	vascular endothelial growth factor
PI3 K:	phosphoinositide-3 kinase	VEGFR-2:	vascular endothelial growth factor kinase receptor-2

Introduction

Licorice (*Glycyrrhiza* in botany, Gancao in Chinese), a perennial herb that extensively grows wild in China, Japan, Russia, Spain, and India, is one of the best-known and most frequently used herbal medicines worldwide [1]. In China, licorice was first recorded in Sheng Nong's herbal classic (Sheng Nong Ben Cao Jing in Chinese), the earliest TCM code, and belongs to "top-grade" herbs (herbs with the lowest side effects or nontoxic usefulness for health care) [2]. Licorice has been subsequently recorded in numerous classic TCM writings and famous prescriptions, such as in one of the earliest TCM books, Treatise on Exogenous Febrile Disease (Shang Han Lun in Chinese), and 70% of prescriptions have included licorice [3]. In Japan, GL (one of the main compounds from licorice) preparation (Stronger Neo-Minophagen C) has been clinically used as an antihepatitis and antiallergic agent for more than 60 years [4]. Licorice is traditionally used to improve health, lengthen life span, and cure coughs or stomachaches [5].

At present, more than 400 compounds have been isolated from licorice and demonstrated a variety of pharmacological activities, such as anticancer, anti-inflammatory, antiviral, hepatoprotective, expectorant, and memory enhancing activity [6–9]. The triterpene saponins of licorice, especially GL (about 1.84% to 9.82% of licorice, depending on the sources and methods of extraction), are the major constituents and bioactive ingredients of licorice, and more than 18 saponins have been isolated from licorice [9–12]. Flavonoids (about 1.78% to 4.82% of licorice, depending on the sources and methods of extraction) are the other main bioactive compounds from licorice, and more than 300 flavonoid compounds have been identified, including LT, ISLT, LG, ISLG, LCA, and GBD [9, 11, 13, 14]. In the 2010 edition of the Chinese Pharmacopoeia, GL and LT are selected as the biomarkers for licorice, and GL and LT content should exceed 2% and 0.5%, respectively [15]. In addition, a series of polyphenols and polysaccharides obtained from licorice have indicated remarkable bioactivity, such as anticancer and immunopotentiating effects [16–18]. The pharmacological effects of licorice, including anti-inflammatory, antiviral, and hepatoprotective effects, were documented in 2008 [6]. However, in recent years, more compounds, especially flavonoids, have been isolated and identified from licorice and have been demonstrated to possess evident anticancer properties both *in vitro* and *in vivo*. Therefore, reviewing and summarizing the anticancer effects and mechanisms of mixtures and purified compounds from licorice is necessary to better understand the

anticancer properties of licorice and to provide data that may be useful for future anticancer research on this herb.

Mixtures from Licorice

The mixed extracts of licorice can generally be acquired using aqueous or organic solutions. Aqueous solutions are mainly used to isolate crude extracts, whereas organic solvents, including methanol, ethanol, trichloromethane, and hexane, are utilized to obtain purified compounds. At present, several mixtures from licorice have been demonstrated to possess anticancer properties both *in vitro* and *in vivo* by inhibition of proliferation and induction of cell cycle arrest, apoptosis, and autophagy.

Inhibition of proliferation

Trichloromethane, hexane, ethyl acetate, and 70% MEL inhibit the proliferation of human breast cancer cell MCF7 in concentration- and time-dependent manners [19]. The 70% MEL also inhibits the cell proliferation of the hepatocellular carcinoma cell HepG2 [20] and human monoblastic leukemia cell U-937 [21] in a concentration-dependent manner. The 70% EEL shows concentration- and time-dependent cytotoxicity to human breast cancer cell MDA-MB-231 [22] and human prostate cancer cell LNCaP [23]. In human prostate cancer cell DU 145 and human colon cancer cell HT-29, the ethanol extracts of roasted licorice exhibit considerably higher cytotoxicity than that of the ethanol extract of unroasted licorice, and the active compound of the ethanol extracts of roasted licorice is LCA [24]. Besides, the purified fraction (diethyl ether, chloroform, and water fraction from the EEL) exhibits higher proliferative inhibition on MCF7, human stomach adenocarcinoma cell AGS, and human hepatocellular carcinoma cell Hep3B and less cytotoxicity to human normal hepatic cell WRL-68 compared with the EEL [25].

Induction of cell cycle arrest

The 80% EEL induces G1 cell cycle arrest in MCF7 by increasing the expression of p53 and p21 proteins and decreasing cyclin E and CDK2 protein expressions [26]. The HEEL also induces G1 phase arrest by the reduction of the protein expression of cyclin A, cyclin D1, CDK2, and CDK4 in DU 145 and murine mammary cancer cell 4T1. A further study also indicates that the active compound in HEEL may be IAA [27]. In addition, G2/M cell cycle arrest in LNCaP and human breast cancer T47D cells is observed with 70% EEL and EEL treatment, respectively [23, 28].

Induction of apoptosis

The EEL induces apoptosis in MCF7 cells with the activation of Bax, PARP, and caspase-7 proteins as well as the inhibition of the expression or induction of the phosphorylation of the Bcl-2 protein [26,28]. In LNCaP cells, the 70% EEL (228 µg/mL) stimulates apoptotic effects by activation of the caspase-dependent pathway and dissipation of the MMP, while pretreatment with Z-VAD-FMK completely abolishes licorice-induced apoptotic cell death [23]. HEEL also excites apoptosis in DU 145 and 4T1 cells by activating caspase-9, caspase-8, caspase-7, caspase-3, and PARP, upregulating Fas and DR4, and inducing the dissipation of the MMP and the release of cytochrome c [27,29]. In addition, the 70% MEL induces apoptosis in U-937 cells [21].

Induction of autophagy

The treatment of 228 µg/mL 70% EEL for 24 h in LNCaP cells induces autophagy-related cell death by the downregulation of the Bcl-2 protein and inhibition of the mTOR pathway [23].

Inhibition of angiogenesis

The 50% ethanol (volume, CH₃CH₂OH:H₂O = 50:50) extracts of licorice inhibits angiogenesis by reducing the VEGF level and microvessel density count in the peritoneum of Ehrlich ascites tumor cells in EAT-bearing mice [30].

In vivo anticancer effects

In 4 T1-injected female BALB/c mice, the addition of HEEL (5 mg/kg) to drinking water inhibits the tumor volumes by reducing the expression of CDK2, CDK4, and PCNA proteins, without affecting the body weight of the mice [27]. I.p. of MEL (500 µg) or aqueous extracts of licorice (600 µg) for 7 d inhibits the growth of EAT cells and the formation of ascitic fluid in EAT-bearing mice by angiogenesis inhibition [30]. In MDA-MB-231 xenograft Balb/c mice, p.o. of 70% EEL (2 mg/kg, once per day for 5 consecutive days, followed by a weekly administration for 44 d) blocks tumor progression [22]. In addition, in mouse colon carcinoma cell CT26 xenograft BALB/c mice, treatment of 0.5, 1, and 2 mg/kg of the 95% ethanol (volume, CH₃CH₂OH:H₂O = 95:5) extracts of licorice (95% EEL) inhibits tumor volume by 38%, 57%, and 71%, respectively. The combined treatment of 2 mg/kg 95% EEL and cisplatin evidently decreases cisplatin-induced nephrotoxicity and hepatotoxicity by inhibiting of cisplatin-induced oxidative stress [31].

Purified Compounds from Licorice

A panel of purified anticancer compounds has been isolated and identified from licorice (● Fig. 1), including triterpenoids GL and GA, flavonoids ISLG, LCA, LCB, LCE, LG, IAA, GBD, ISLT, and LRD, phenolic LCM, GLY, and β-hydroxy-DHP. Among these substances, GA, ISLG, and LCA have been extensively studied and present evident anticancer effects by inhibiting cancer cell proliferation, inducing cell cycle arrest, apoptosis, and autophagy, and inhibiting metastasis and angiogenesis.

Triterpenoids

Triterpenoids are the main ingredients and characteristic compounds in licorice. More than 18 triterpenoid saponins, such as GL, GA, licorice-saponin A3, and licorice-saponin L3, have been isolated [9]. At present, GL and its aglycone GA have been widely demonstrated to present evident anticancer effects both *in vitro* and *in vivo*. In addition, GL and GA have been utilized as hepatic

targeting ligands in targeted drug delivery systems for HCC treatment because of highly expressed target binding sites in liver cells [32,33].

Glycyrrhizic acid

Inhibition of proliferation: GL (100 µM) exhibits no or slight cytotoxicity on several types of cancer cells, such as melanoma cells SK-MEL-2, SK-MEL-28, and B16 as well as human cervix tumor cell SiHa [34–36]. Meanwhile, the inhibitory effect of GL on cancer cells emerges at relatively higher concentrations. GL inhibits mouse leukemia cell WEHI-3 and human leukemia cell TF-1 in a dose-dependent manner [37,38]. The treatment of HepG2 with GL for 24 h exhibits an IC₅₀ of more than 1.2 mM [39]. In addition, the proliferation and growth of human lung cancer cell A549 [40], glioblastoma cell U251 [41], and human prostate cancer cells LNCaP [42] and DU 145 [42] are inhibited by GL with IC₅₀s at the millimole level.

Induction of cell cycle arrest: The 200 µM to 400 µM GL concentration range induces dose- and time-dependent G0/G1 phase arrest in WEHI-3 cells [37].

Induction of apoptosis: GL triggers apoptotic cell death in various cancer cells, such as WEHI-3 [37], LNCaP and DU 145 [42], MCF7 [43], U251 [41], and A549 [40]. This activation may be mediated by the promotion of ROS production [37], reduction of MMP [37], deactivation of the NF-κB pathway [41], and induction of DNA damage [37,42].

Inhibition of metastasis: In a melanoma cell B16F10-implanted mouse model, GL inhibited pulmonary metastasis by regulating tumor-associated T helper type 2 cells [44]. GL also inhibited human leukemia cell TF-1 migration via inhibition of the Akt/mTOR/STAT3 cascade [38].

Inhibition of angiogenesis: A previous study indicated that 82 µg/mL GL increases tube formation, which is critical for angiogenesis [45]. However, recent studies suggest that the “no cytotoxicity concentration” of GL (100 µM) decreases the angiogenic activity of bladder cancer cell ECV304 by decreasing motility, invasion, and tube-forming properties by blocking ROS generation and extracellular ERK activation [46].

Chemosensitization or radiosensitization: GL reverses cisplatin resistance in the hepatocellular carcinoma cell Huh7 by inhibiting cisplatin efflux from the cells [47]. Pretreatment of 30 µM of GL enhances UVB-induced apoptosis in SK-MEL-28 cells [35]. Furthermore, GL is identified as an inhibitor of Ku86, one of the key proteins in reducing radiotherapy efficacy by repairing DNA breaks on cancer cells [48]. In SKH-1 mice, UVB-induced cancer formation and apoptotic sunburn cells can be blocked by pretreatment with GL [49].

Others: The overexpression of the HMGB1 protein often results in cancer cell proliferation and motility as well as angiogenesis [50–53]. GL can directly inhibit the DNA binding activity of HMGB1 to decrease tumor proliferation [52,54,55]. GL inhibits proliferation and induces apoptosis in A549 cells (TxAS protein overexpression) by inhibiting TxAS expression and activity. However, the antiproliferative effect of GL disappears with TxAS protein knock-down. Interestingly, GL cannot inhibit lung cancer cell NCI-H23 proliferation (TxAS protein low expression). When NCI-H23 cells are transfected with TxAS cDNA, GL completely suppresses the growth of NCI-H23 cells [40]. In addition, GL inhibits the activity of NAT and DNA-2-aminouorene adduct formation in colon cancer cell COLO 205 [56]. This combination of NAT and DNA-2-aminouorene is associated with the increased risk of several types of cancer [57–59]. Several hepatic TDDS utilizing GL as a hepatic lig-




Fig. 1 Chemical structures of the anticancer compounds isolated from licorice.

and have been developed, such as GL modified O-carboxymethyl chitosan nanoparticle loaded paclitaxel [60], GL modified N-caproyl chitosan nanoparticles [61], and GL modified chitosan nanoparticles [62]. These nanoparticles preferentially accumulate in HCC cells to enhance anti-HCC effects and to reduce the side effects of chemotherapeutics.

In vivo anticancer effects: Several *in vivo* anticancer research studies on GL have been conducted. In an ovariectomized mouse model, GL (p.o.) suppressed M-methyl-N-nitrosourea solution-induced endometrial cancer progress by inhibiting the expression of COX-2, TNF- α , and IL-1 [63]. In Renca cell-implanted BALB/c mice, GL (p.o., 50 mg/kg, once a day for a week) suppressed about 35% of tumor weight and 60% of tumor volume by reducing angiogenesis [46]. In acetate-induced hyperproliferative activity in Wistar rats, GL (p.o., 300 mg/kg, 5 d), before acetate i.p., significantly inhibited tumor promotion by decreasing ODC activity and DNA synthesis [64]. In A549 tumor xenograft nude mice, GL (i.p., 50 mg/kg) also inhibited tumor growth by inhibition of TxA2 expression [40]. In addition, p.o. of GL in drinking water to SENCAR mice inhibited TPA- and DMBA-induced skin tumorigenesis by decreasing ODC activity and DNA synthesis [65,66]. I.m. of BALB/c mice with GL (2 mg) also decreased

the diethylnitrosamine-induced incidence rate of hepatocellular carcinoma from 64% to 21% [67].

Glycyrrhetic acid

Inhibition of proliferation: GA inhibits cell proliferation in a series of cancer cells, including human cervix cancer cell SiHa [34], melanoma cells 518A2 [68], SK-MEL-2, and SK-MEL-28 [35], HCC cell HepG2 [39], human epithelial ovarian cancer cells OVCAR-3 and SK-OV-3 [69,70], gastric cancer cells BGC823 and SGC7901 [71], human breast cancer cell MCF7 [68,72], lung cancer cells NCI-H460 and A549 [68,73], human pharynx cancer cell FaDu, human submandibular cancer cell A-253, human skin cancer cell A-431, anaplastic thyroid cancer cells 8505 C and SW1736 [68], human prostate cancer cells LNCaP and DU-145 [74], colon cancer cells DLD-1, HCT 116, HCT-8, HT-29, and SW480 [68,75], human bladder cancer cell NTUB1 [76], and human promyelocytic leukemia cell HL-60 [77]. In addition, GA exhibits the most tumor-selective toxicity among other clinical drugs (adriamycin, cisplatin, cytarabine, etoposide, fluorouracil, and manumycin A) through GSH downregulation [78–80]. The same GA concentration also inhibits the proliferation of MCF7 cells without affecting immortalized normal mammary epithelial cells [81].

Induction of cell cycle arrest: GA obviously induces G1 phase arrest in HepG2, A549, and NCI-H460 cells in a concentration-dependent manner [39,82]. In BGC823 and SGC7901 cells, GA triggers G2 phase arrest in concentration- and time-dependent manners by upregulation of p21 and downregulation of cdc2 and cyclin B1 expression [71].

Induction of apoptosis: GA induces apoptosis in a panel of cancer cells, including HepG2 [39,83], SK-MEL-2 [35], DU 145 [74], SiHa [34], stomach cancer cell KATO III [71,84], HL-60 [77,84], NCI-H460 and A549 [68,73], BGC823 and SGC7901 [71], and MCF7 [72,81] with the activation of caspase-8 [39], caspase-9 [39,73,81], caspase-3 [34,73], PARP [41,73], Bax [81], and Bim [81] as well as the inhibition of the protein expression of Bcl-xL [39,73], Bcl-2 [39,73,81], Bid [71], and connexin 32 [39]. The induction of MMP dysfunction [34,81] and DNA damage [39,81], increase of the intracellular Ca²⁺ concentration [72] and cytochrome c release [34,71,81], upregulation of ROS generation, depletion of glutathione [34], and reduction of Akt kinase activity [81] all participate in GA-induced apoptosis. GA also induces apoptosis by suppressing the pro-survival mediator phosphorylation of PKC α/β and activating the JNK kinase. Pretreatment of the PKC promoter or JNK inhibitor reverses GA-induced apoptosis [73]. Furthermore, GA potentiates the Hsp90 inhibitor- and trichostatin A-induced apoptotic effect by activation of the caspase-8- and Bid-dependent pathways [69,70].

Induction of autophagy: GA obviously induces autophagy in a concentration-dependent manner by activation of the ERK pathway in HepG2 and Hep3B cells, and inhibition of autophagy by chloroquine or bafilomycin A1 increases the GA-induced apoptosis, suggesting that the GA-stimulated autophagy might decrease its anticancer effects [83].

Inhibition of metastasis: GA concentration dependently inhibits the metastasis of LNCaP cells by downregulating MMP-9 and VEGF via inhibition of PI3K/Akt-mediated NF- κ B activity [85]. GA also inhibits tube formation of HUVECs and invasion of DU-145 cells by decreasing the expression of NF- κ B, VEGF, and MMP-9 [74]. In breast cancer cells, GA inhibits MMP-2 and MMP-9 expression via breaking p38-AP1 signaling [86].

Chemosensitization or radiosensitization: Combined treatment of 50 μ M GA evidently enhances the antiproliferative and proapoptotic effects of mitomycin c, doxorubicin, and camptothecin in SiHa cells [34]. The proliferative inhibition of vinblastine in P-glycoprotein-overexpressing human carcinoma KB-C2 and doxorubicin in KB/MDR cells are also enhanced with the combined treatment of GA [87].

Others: GA induces anoikis-like cell death and disturbs cytoskeletal protein expression in central nervous system tumorigenic cells [88]. In NSCLC cells, GA inhibits cell proliferation by inhibiting the activity of the thromboxane synthase protein, which is overexpressed in NSCLC and carries a poor prognosis [89]. GA also reverses hepatic stellate cell-mediated immunosuppression by enhancing the ability of T cells to attack tumor cells in the tumor microenvironment [90]. In addition, GA inhibits the aldo-keto reductase 1B10, which has been recently identified as a tumor marker in several types of cancers [91]. Furthermore, GA has been widely utilized as a liver ligand in HCC TDDS to enhance the anticancer effects and to reduce the side effects of chemotherapeutic drug-loaded nanoparticles [92–94].

In vivo anticancer effects: In an SGC7901 xenograft nude mice model, subcutaneous injection of GA (30 mg/kg) inhibited the average weight of the subcutaneous tumor from 2.8 g to 0.7 g and induced apoptosis by decreasing the expression of Bid [71].

In DMBA- and TPA-induced skin tumors in SENCAR mice, GA pretreatment resulted in the protection against tumor initiation and promotion [95]. In hepatoma cell H22-bearing mice, an i.v. of GA-modified alginate nanoparticle-loaded doxorubicin (7 mg/kg doxorubicin, once every 4 d for 16 d) evidently inhibited tumor growth as evidenced by the tumor weight inhibitory rate and the mean tumor volume of about 76.6% and 2.9 mm³ in the GA-modified alginate nanoparticle loaded doxorubicin group, respectively, compared with 52.6% and 9.2 mm³ in the doxorubicin group. In addition, the side effects of doxorubicin are obviously decreased after being loaded with GA-modified alginate nanoparticles [96].

Flavonoids

The flavonoids of licorice include various types, such as flavanones or flavanones (LG, LT, and licoflavanone), chalcones (ISLG, ISLT, LCA, LCB, and LCE), isoflavans (IAA, GBD, and LRD), and isoflavones (glabrone, licoisoflavone A, and gancaonin H) [9]. These flavonoids present significant anticancer, antioxidative, antimicrobial, and antiviral effects among others. [6,97,98]. According to this study, chalcones, ISLG, LCA, and IAA, in particular, are licorice anticancer compounds that act mainly by the induction of cell cycle arrest, apoptosis, and autophagy as well as the inhibition of metastasis and angiogenesis.

Isoliquiritigenin

Inhibition of proliferation: ISLG inhibits cell proliferation in human cervical cancer cells C-33 A, Ca Ski, HeLa, SiHa, and U14 [99–102], gastric cancer cells AGS, MKN-28, MKN-45, and SGC7901 [103], colon cancer cells COLO 320DM, Colon 26, CT26, HCT 116, HT-29, and RCN-9 [104–106], prostate cancer cells C4-2, DU 145, and LNCaP [107–109], myeloma cells ARH-77, CZ-1, MPC-11, RPMI 8226, SP2/0, and U266 [110], breast cancer cells MCF7 and MDA-MB-231 [111,112], human promyelocytic leukemia cell HL-60 [113], lung cancer cells A549, HCC827, NCI-H1650, and NCI-H1975 [114–116], human epithelial ovarian cancer cell SK-OV-3 [117], human glioma cell U-87 [118]; mouse renal cancer cell Renca [119], HCC cell HepG2 [120–122], and mouse melanoma cell B16-F0 [123] in time- and dose-dependent manners. Furthermore, ISLG presents lower toxicity to normal cells (gingival fibroblast cell HGF, periodontal ligament fibroblast cell HPLF, normal myometrium cells, and normal intestinal epithelial tissue cell IEC-6) [108,109,124,125] than to cancer cells (oral cancer cells HSC-2 and HSC-3, submandibular gland cancer cells HSG and HL-60, and uterine leiomyoma cells), indicating that ISLG may be a promising lead compound for cancer therapy.

Induction of cell cycle arrest: The phase of cell cycle arrest induced by ISLG varies among the cancer cells and treatment time. ISLG induces cell cycle arrest in U266 [110], C-33 A, Ca Ski, HeLa, SiHa, U14 [99,101,126], HCT 116 [104], A549 [114], HepG2 [122], uterine leiomyoma cells [125], and oral squamous cell carcinoma [127]. ISLG induces G2/M phase arrest by decreasing the protein expression of CDK2, cyclin B, cyclin A, cdc2, cdc25 C, and human papillomavirus type 16 E6 [99,101,104,125], activating the Rb, p53, p21, and ataxia telangiectasia mutated proteins [99,101,114,115,122,125,126], inducing DNA damage [126], and inhibiting the activity of topoisomerase II [99]. In U-87 cells, ISLG induces both S and G2 phase arrest by inducing the expression of p21 and p27 [118]. In MPC-11 cells, ISLG hinders the G1 phase [110]. Interestingly, the cell phase arrest by ISLG in DU 145 is time-dependent. Within 2 h of treatment, ISLG induces G1 arrest by decreasing the protein expression of cyclin D1, cyclin E, and

CDK 4 and increasing p27 expression [128], whereas ISLG induces S and G2/M arrest within 4 h to 24 h treatment by increasing the expression of cyclin B and phosphorylation of cdc2 [107, 128]. The ISLG-induced cell cycle arrest in A549 is controversial. Li et al. reported that ISLG induces G2/M arrest in A549 in concentration- (15, 30, and 40 μM after 24 h treatment) and time-dependent (40 μM after 4, 8, 16, and 24 h treatment) manners by upregulating p21 mRNA [114]. However, Hsu et al. indicated that ISLG treatment (20 and 40 μM) for 24 h induces G1 phase arrest with the increasing protein expression of p53 and p21 [115].

Induction of apoptosis: ISLG induces apoptosis in various cancer cells, such as HT-29, HCT 116, COLO 320DM, and Colon 26 [104, 106, 129, 130], MCF7 and MDA-MB-231 [111, 131], HepG2 [120–122], HeLa [99–101], Ca Ski, SiHa, C-33 A [101], U266 [110], DU 145 [109], SK-OV-3 [117], HL-60 [124], A549, HCC827, NCI-H1650, and NCI-H1975 [115, 116], U-87 [118], adenoid cystic cancer cells ACC-2 and ACC-M [132], gastric cancer cell MGC-803 [133], and uterine leiomyoma cells [125] by activating caspase-9 [99, 101, 109, 111, 124, 130], caspase-8 [101, 109, 122, 124], caspase-7 [109], caspase-3 [101, 104, 106, 109, 111, 124, 125, 132], PARP [100, 101, 104, 109, 111, 125, 132], Bax [99, 101, 109, 120, 122, 132, 134], Bak [99], Fas [109, 115, 122, 125], FasL [109], and Bid [109] as well as inhibiting Bad [111], Bcl-xL [99, 104, 110, 111, 121, 134], and Bcl-2 [99, 101, 104, 110, 120, 121, 125, 132] activities.

Potential mechanisms may involve downregulating the arachidonic acid metabolic network by inhibiting the mRNA expression of multiple key enzymes, such as phospholipase A2, COX-2, and cytochrome P450 4A [111], deactivating the PI3 K/Akt and NF- κ B pathways [111, 121], increasing the protein expression of p53 and p21 [101, 122], increasing intracellular ROS production [100, 117, 120], triggering ER stress by the upregulation of ER stress-related molecules α -subunit of eukaryotic initiation factor 2, 78 kDa glucose-regulated protein, X-box binding protein 1 expression, and cleavage of activating transcription factor 6 α [117], thus enhancing the concentration of intracellular Ca^{2+} [133], inducing MMP dysfunction [99, 101, 109, 133], and increasing the release of mitochondrial cytochrome c [101, 109, 111]. In addition, the decreased protein expression of human papillomavirus type 16 E6 and cellular inhibitors of apoptosis protein expression [101, 121] and the enhanced release of smac/diablo from the mitochondria into the cytoplasm [109] as well as inhibited glucose transmembrane transport [134] are also observed in ISLG-induced apoptosis.

Induction of autophagy: Both *in vitro* and *in vivo* studies have demonstrated that ISLG activates autophagy by suppressing the mTOR pathway in adenoid cystic carcinoma cells, and the inhibition of autophagy obviously decreases the ISLG-induced cell death [132].

Induction of differentiation: In HL-60 cells, 10 $\mu\text{g}/\text{mL}$ ISLG changes the cell morphology from round to star shape by enhancing the protein expression of terminal differentiation markers CD11b and CD14 and increasing the nitroblue tetrazolium chloride reductive activity [113]. ISLG also induces B16-F0 cell differentiation with morphological changes, ROS generation, and melanogenesis. However, pretreatment with an ROS inducer or scavenger either increases or depletes ISLG-induced cell differentiation and melanin secretion [86, 123]. Furthermore, NADPH oxidase-derived ROS generation presents a positive regulation in ISLG-induced HL-60 cell differentiation [135].

Inhibition of metastasis: The epidermal growth factor induced the expression of uPA, MMP-9, VEGF, ICAM, VCAM, and integrin- α 2,

which are essential for cell adhesion, migration, and invasion and are blocked by ISLG by decreasing the DNA binding activity of AP-1 and the phosphorylation of JNK [136]. ISLG also inhibits NF- κ B degradation and ROS generation, subsequently blocking VCAM and E-selectin expression to inhibit the adhesion of human endothelial cells [137, 138]. In addition, in highly metastatic MDA-MB-231 cells, the nontoxic concentration of ISLG (10 μM) inhibits the secretion and protein expression of VEGF, MMP-2, and MMP-9 by inhibiting hypoxia-inducible factor 1- α protein expression, decreasing p38 and PI3 K/Akt activity, and inhibiting the DNA binding activity of NF- κ B [112]. ISLG also decreases COX-2 and CYP 4A signaling to inhibit MDA-MB-231 and BT-549 metastasis by preventing anoikis resistance, migration, and invasion [131]. Furthermore, in Renca xenograft BALB/c male mice, 0.1, 0.5, 2, and 10 mg of ISLG (*i.p.*, once a day for 10 d) decreases 40.59%, 45.59%, 60.00%, and 68.23% of metastatic nodules in the lung, respectively, by decreasing the amount of VEGF and activating the immune system. These ISLG doses are approximately 1/6 to 1/600 of the lethal dose 50 [119].

Inhibition of angiogenesis: Previous *in vitro* and *in vivo* studies have demonstrated that the antiangiogenesis effect of the water extractions of licorice root mainly depend on ISLG, which exhibits the most antitube formation ability among other licorice-derived flavonoids [45, 139]. In addition, the phorbol myristate acetate-induced motility, tube formation, and activation of MMP-2 can be inhibited by ISLG treatment by blocking the JNK and p38 pathways in HUVECs [140]. Furthermore, after treating MDA-MB-231 implanted Balb/c mice, ISLG (*p.o.*, 10 mg/kg, 5 times a week for 5 weeks) remarkably decreased the number of lung surface metastases by decreasing the intratumoral levels of MMP-2 and MMP-9 [131].

Chemosensitization or radiosensitization: Pretreatment of 10 $\mu\text{g}/\text{mL}$ ISLG for 6 h evidently enhances the radiosensitivity of HepG2 through the disturbance of the redox status and inhibition of nuclear factor erythroid-2-related factor 2 expression [120]. In cervical cancer cells, the combined treatment of ISLG upregulates the inhibitory effects of CP both *in vitro* and *in vivo*, and the CP-induced genotoxic activity is decreased by the inhibition of DNA strand breaks in white blood cells and micronucleus formation in polychromatic erythrocytes [102]. Furthermore, in CT26 colon carcinoma cell inoculated BALB/c mice, ISLG (*p.o.*, 1 mg/kg) inhibits tumor growth by 52%. By combining with cisplatin, the tumor growth inhibition of the combination is enhanced to 79%, and cisplatin-induced nephrotoxicity and hepatotoxicity are alleviated [105].

Others: ISLG also regulates the expression and activity of certain cancer-related enzymes. The polymorphisms of the CYP19 enzyme have been implicated in the etiology of breast cancer [141, 142]. In wild-type MCF7 cells, ISLG inhibits the protein expression and transcriptional activity of CYP19 by inhibiting the MEK/ERK pathway and the activity of promoters I.3 and II [142]. ISLG decreases polycyclic aromatic hydrocarbon-induced expression, which is associated with the initiation of cancer, by antagonizing aryl hydrocarbon receptor translocation [143]. ISLG also inhibits mammary carcinogenesis by decreasing breast cancer stem cells [144]. Furthermore, ISLG inhibits the ErbB3 protein, which is frequently observed in human cancer cells and currently constitutes the primary target of anticancer strategies [145].

***In vivo* anticancer effects:** The *in vivo* anticancer effects of ISLG in several animal models have also been documented. In MDA-MB-231 xenograft nude mouse models, treatment of ISLG (*i.p.*, 100 mg/kg) for 5 weeks evidently decreases tumor weight

by 62.3% by decreasing the intratumoral PGE₂, 220-HETE, and phosphorylation of Akt levels and by inducing the expression of intratumoral cleaved caspase-3 and cleaved PARP productions [111]. In U266 xenograft SCID mice, ISLG (i.p.) decreases tumor volume by decreasing the expression of IL-6 and MVD as well as the phosphorylation of ERK and STAT3 [110]. In ACC-M cell-implanted BALB/c nude mice, ISLG (p.o., 0.5 g/kg, 30 d) inhibits tumor growth by the induction of mTOR-dependent autophagic and apoptotic cell death [132]. In ddY mice, ISLG (p.o., 15 ppm in drinking water) suppresses the AOM-induced colonic aberrant crypt focus and cancer formation, with an inhibitory ratio of 37.3% [146].

Licochalcone A

Inhibition of proliferation: LCA dose- and time-dependently inhibits cell proliferation of several kinds of cancer cells, such as MKN-28, SGC7901, AGS, and MKN-45 [103], HepG2, Hep3B, and SNU878 [147], LNCaP [23, 148], prostate cancer cell PC-3 [149], colon cancer cells CT26 and HCT-15 [150, 151], OVCAR-3 and SK-OV-3 [151, 152], HeLa [153], bladder cancer cell T24 [154, 155], A549 [151], oral squamous cancer cells HN22 and HSC4 [156], and malignant pleural mesothelioma cells MSTO-211 H and H28 [127], gastric cancer cell BGC-823 [157]. LCA presents the highest cytotoxicity against multiple gastric cancer cells and the lowest cytotoxicity to the normal human gastric epithelial cell GES-1 compared to the cell cytotoxicity of licorice compounds (ISLG, LCA, GA, GBD, GL, etc.) [103]. Furthermore, the obvious antiproliferative concentrations of LCA on cancer cells exhibit no or only slight cytotoxicity to human normal liver cells [147], human normal gastric epithelial cells [103], and human primary normal oral keratinocytes [158].

Induction of cell cycle arrest: The phase of cell cycle arrest induced by LCA varies according to the kind of cancer cells. In rat vascular smooth muscle cells, pretreatment with LCA evidently suppresses platelet-derived growth factor-induced cell proliferation by inducing G1 phase arrest through decreasing the protein expression of cyclin A, cyclin D, CDK2, and CDK4, inhibiting the phosphorylation of Rb and ERK, and increasing the protein expression of p27 [159]. Induction of G1 phase arrest by LCA is also observed in LNCaP cells [23]. However, in MKN-28 and PC-3 cells, LCA induces G2 phase arrest by reducing the protein expression of cyclin A, cyclin B, cyclin D, cyclin E, cdc2, CDK4, and CDK6 as well as the phosphorylation of Rb [103, 149].

Induction of apoptosis: LCA presents proapoptotic effects in bladder cancer cell T24 [155], cervical cancer cell HeLa [153], HepG2 [34, 147], OVCAR-3 and SK-OV-3 [152], MKN-28, AGS, and MKN-45 [103], LNCaP and PC-3 [23, 148, 149], KB, HSC4, and HN22 [156, 158], MCF7 [160], and BGC-823 [157] as well as HL-60 [160] by activating caspase-9 [147, 152, 155], caspase-8 [152, 158], caspase-4 [147], caspase-3 [147, 152, 155, 156, 158], PARP [103, 147, 152, 155, 158, 160], Bax [103, 152, 155], FasL [158], and p53 [152] proteins as well as inhibiting Bcl-2 [103, 152, 155, 160], Bid [152], Bcl-xL [152], and survivin [152] activity. Triggering ER stress [155], elevating ROS generation [155, 157], and inducing MMP dysfunction [152, 155] may be the potential mechanisms for LCA-induced apoptosis.

Induction of autophagy: 12.5 μM of LCA induces autophagic cell death by the inhibition of Bcl-2 and mTOR in LNCaP cells, as evidenced by the conversion of the cytosolic form of microtubule-associated protein light-chain 3 to a lipidized form as well as abundant autophagic vacuole formation [23].

Inhibition of metastasis: In oral squamous cancer cell SCC-25, 50 μg/mL of LCA evidently inhibits the motility, adhesion, migration, and invasion of cancer cells with decreased MMP-2 and NF-κB activities [161].

Inhibition of angiogenesis: The antiangiogenesis effects of LCA were also studied. The proliferation, migration, and tubule formation of HUVECs are inhibited by 20 μM of LCA treatment with decreasing levels of IL-6 and IL-8. To further study the mechanisms, the VEGF-stimulated phosphorylation of VEGFR-2 is blocked by LCA. Upon VEGFR-2 protein knockdown, the LCA-stimulated inhibitory effect on proliferation, migration, and tube formation of HUVECs is depleted [162]. LCA also inhibits platelet-derived growth factor-induced rVSMC proliferation by decreasing the phosphorylation of ERK [159]. In a CT26 transplant BALB/c mice model, LCA (p.o., 30 mg/kg, daily for 2 weeks) inhibits tumor growth with an average tumor size from 899 ± 59 mm³ to 333.9 ± 53.8 mm³ by the inhibition of tumor angiogenesis and the promotion of apoptosis [162].

Chemosensitization: Treatment with 7.5 μM of LCA increases 10 μM of geldanamycin-induced cell death from 36% to approximately 74% in OVCAR-3 cells by enhanced geldanamycin-induced apoptosis-related protein activation and ROS formation, whereas the combined effect is decreased by the addition of oxidant scavengers [163]. In addition, the antiproliferative effects of paclitaxel and vinblastine can be enhanced by the combined treatment with LCA [160].

Others: LCA inhibits the proliferation of A549, SK-OV-3, SK-MEL-2, and HCT-15 by inhibiting the activation of Top I in a concentration-dependent manner [151]. LCA also inhibits cell proliferation and survival by inhibiting the phosphorylation and nuclear localization of STAT3 [164].

In vivo anticancer effects: In the AOM/dextran sulfate sodium-induced colon carcinogenesis in C57BL/6 mice, 5, 15, and 30 mg/kg of LCA (p.o.) present approximately 41%, 75%, and 98% inhibitory rates in cancer growth, respectively. In addition, tumor metastasis is inhibited by decreasing MMP-9 activity [165]. DMBA-initiated and TPA-promoted mouse skin papilloma are also inhibited by LCA [166]. In addition, in CT26 cell injected Balb/c mice, LCA (p.o.) obviously reduces cisplatin-induced nephrotoxicity and hepatotoxicity by blocking cisplatin-induced oxidative stress without affecting the chemotherapeutic efficacy of cisplatin [150].

Licochalcone B

LCB inhibits the proliferation of bladder cancer cells T24, EJ, and MB49 by inducing S phase cell cycle arrest and apoptosis through the reduction of cyclin A, CDK1, CDK2, cdc25 A, cdc25B, Bcl-2, and survivin expression as well as the enhancement of Bax expression. In MB49 xenograft C57BL/6 mice models, LCB has been shown to inhibit cancer cell growth without evident toxicity to mice by assessing mice weight, serum glutamate oxaloacetate aminotransferase, and glutamate pyruvate aminotransferase [167].

Licochalcone E

LCE inhibits the proliferation of A549, SK-OV-3, SK-MEL-2, and HCT-15 by reducing Top I activity, DNA binding activity of NF-κB, and Bcl-2 expression [151, 168]. LCE dose-dependently inhibits the migration and invasion of MDA-MB-231 and 4T1 cells by decreasing the secretion of uPA, VEGF, and MMP-9. Furthermore, in 4T1 xenograft BALB/c mice models, LCE (p.o., 14 mg/kg) suppresses tumor growth and metastasis by reducing the expression

of Ki67, CDK4, CDK2, cyclin A, cyclin D, VEGF, lymphatic vessel endothelial receptor-1, COX-2, and hypoxia inducible factor-1 as the protein expressions of Bax and cleaved caspase-3 are increased [169].

Liquiritigenin

The antiproliferative effects of LG in hepatic cancer cell SMMC-7721 and HeLa cells are mainly achieved by the induction of apoptosis with the upregulation of Bax and caspase-3 proteins as well as through the inhibition of the expression of Bcl-2 and survivin by increasing the generation of ROS, activating p53, inducing MMP dysfunction, and decreasing GSH and the activities of superoxide dismutase. Meanwhile, in pretreatment with an ROS scavenger, LG-induced apoptosis is obviously decreased [170, 171]. The noncytotoxic concentration of LG inhibits the adhesion and migration of A549 cells by decreasing MMP-2 activity, hindering phosphorylation of Akt, and activating ERK [172]. Moreover, LG inhibits the expression of VEGF in HeLa cells in a dose-dependent manner. In HeLa-implanted nude mice, i.g. of LG (40 mg/kg, once a day for 28 d) also exhibits a more than 50% inhibitory rate on tumor growth by decreasing VEGF and MVD expression [173]. Furthermore, in the H22 bearing mice model, treatment of LG (i.g., 20 mg/kg) inhibits the tumor growth by decreasing MDA content and inducing apoptosis [174].

Isoangustone A

The antiproliferation of IAA in SW480 [175], pancreatic cancer cells PC3, LNCaP, and DU 145 [29, 176], 4 T1 [29], and melanoma cells SK-MEL-2, SK-MEL-5, SK-MEL-28, and WM-266-4 [177] are achieved by the induction of cell cycle arrest and apoptosis. IAA induces PC3, LNCaP, SK-MEL-28, DU 145, and 4 T1 cells in G1 phase cell cycle arrest through the reduction of the protein expression of cyclin A, cyclin D, cyclin E, CDK2, and CDK4. This inhibitory effect may be achieved by the downregulation of mTOR, PI3 K, Akt, and JNK activities [27, 176, 177]. IAA also induces apoptosis in SW480 and DU 145 cells by activating caspase-3, caspase-9, PARP, and DR4, suppressing Bcl-2 protein expression, disrupting MMP and ATP synthesis, and inducing cytochrome c release [27, 29, 175]. In addition, the pretreatment of Z-VAD-FMK or knockdown of the DR4 obviously attenuates IAA-induced apoptosis [29, 175]. Furthermore, in PC3 xenograft BALB/c nude mice, IAA (i.p., 5 mg/kg) reduces about 70.0% and 53.6% of tumor volume and tumor weight, respectively, through the inhibition of PCNA expression and the induction of G1 phase arrest [176]. In an SK-MEL-28-injected male BALB/c mice model, 2 or 10 mg/kg IAA (i.p., daily for 5 weeks) inhibits tumor volume and weight without affecting the body weight [177].

Glabridin

The migration, invasion, and epithelial-mesenchymal transition of A549, MDA-MB-231, and HUVECs can be inhibited by GBD treatment by decreasing the FAK, Src, Akt, myosin, and myosin light chain phosphorylation, the FAK and Src interaction, and the RhoA activity [178, 179]. GBD also inhibits the migration and invasion of Huh7 and Sk-Hep-1 cells by decreasing the expression, activities, and protein levels of MMP9, phosphorylation of ERK1/2 and JNK1/2, upregulation of the tissue inhibitor of metalloproteinase-1, and downregulation of the NF- κ B and AP-1 signaling pathways [180]. GBD inhibits angiogenesis in nude mice models [179]. The accumulation of daunorubicin in KB-C2 cells can be enhanced by GBD treatment [87]. Furthermore, the nontoxic concentration of GBD (15 μ M) prevents UVB-irradiated normal

human keratinocyte damage by inhibiting ROS production and cleaved PARP expression [181]. In SK-Hep-1 xenograft BALB/c nude mice, GBD (i.p., 10 mg/kg, three times a week) dramatically suppressed tumor growth without statistically significant changes in body weight [180].

Isoliquiritin

ISLT exhibits a 50-fold greater inhibitory effect on the angiogenesis of granuloma tissue than that of licorice extractions. This inhibitory effect is achieved by inhibiting tube formation [45].

Licoricidin

The noncytotoxic concentration of LRD inhibits the migration and adhesion of DU 145 cells in a concentration-dependent manner through the reduction of MMP-9, uPA, VEGF, integrin- α 2, ICAM, and VCAM secretion [182].

Phenolics

Several licorice phenolics, such as LCM, GLY, and β -hydroxy-DHP, also demonstrated anticancer effects by the induction of cell cycle arrest and apoptosis.

Licocoumarone

LCM inhibits the proliferation of U-937 cells in a concentration-dependent manner through the induction of apoptosis [21].

Glycyrol

In human Jurkat cells, GLY induces S phase cell cycle arrest and apoptosis in time- and dose-dependent manners through the activation of Fas, caspase-8, and caspase-9 proteins [16]. It also induced cell cycle arrest, apoptosis, and defective autophagy in AGS and HCT 116 cells with the activation of the JNK pathway [38]. *1-(2,4-Dihydroxyphenyl)-3-hydroxy-3-(4'-hydroxyphenyl) 1-propanone*: β -Hydroxy-DHP decreases the viability of MCF7 cells in a dose-dependent manner, and this proliferative inhibition is mainly due to induced apoptosis. The 50 μ M concentration of β -hydroxy DHP also induces apoptosis in HL-60 cells and G2/M cell cycle arrest in T47D cells [28].

Discussion and Conclusion



We have summarized the *in vitro* and *in vivo* anticancer properties (● Tables 1 and 2) and potential mechanisms of mixed extracts and purified compounds from licorice (● Fig. 2). A series of licorice compounds have been indicated as possessing anticancer effects by inhibiting cancer cell proliferation and metastasis. Present studies focusing on extracts are rather limited, and the active compounds of extracts are not clear. The anticancer effects of purified compounds, such as GA, ISLG, and LCA, attracted considerably more studies than these extracts. However, most studies focus on the phenomena without detailed mechanism analysis, and *in vivo* anticancer effects are also restrained. In addition, the pharmacokinetic assay and maximum tolerated dose are also important for the development of licorice. Several pharmacokinetic studies of licorice compounds, such as GL, GA, ISLG, and LG, etc., have been carried out in some animal models [183–185]. In an Sprague-Dawley rat model (468 mg/kg of licorice, p.o.), the peak plasma concentrations of LG and ISLG were 2.83 μ g/mL and 0.28 μ g/mL, respectively [186]. However, in a Sprague-Dawley rat model, the peak plasma concentrations of LG (1920 mg/kg, p.o.), ISLG (180 mg/kg, p.o.), GL (170 mg/kg,

Table 1 The antiproliferative properties of licorice compounds *in vitro*.

Compounds	Cancer tissue/disease	Cancer cell	Concentration	Inhibition rate	Method	Ref.
Ethanol extract of roasted licorice	Prostate	DU 145	6 µg/mL	50% (72 h)	MTT	[24]
		MLL	4.3 µg/mL	50% (72 h)	MTT	[24]
	Colon	HT-29	12 µg/mL	50% (72 h)	MTT	[24]
	Breast	MCF-7	30 µg/mL	88% (48 h)	MTT	[24]
		MDA-MB-231	30 µg/mL	82% (48 h)	MTT	[24]
	Melanoma	B16-F10	30 µg/mL	80% (48 h)	MTT	[24]
	Skin	A375	30 µg/mL	94% (48 h)	MTT	[24]
A2058		30 µg/mL	93% (48 h)	MTT	[24]	
Ethanol extract of un-roasted licorice	Prostate	DU 145	12.3 µg/mL	50% (72 h)	MTT	[24]
		MLL	12.2 µg/mL	50% (72 h)	MTT	[24]
	Colon	HT-29	31 µg/mL	50% (72 h)	MTT	[24]
Ethanol extracts of licorice 80% ethanol (volume, CH ₃ CH ₃ OH:H ₂ O = 70:30) extracts of licorice	Breast	MCF7	100 µg/mL	about 25% (72 h)	MTT	[26]
	Breast	MCF7	100 µg/mL	about 50% (72 h)	MTT	[26]
70% methanol (volume, CH ₃ OH:H ₂ O = 70:30) extracts of licorice	Leukemia	U973	50 µg/mL	about 70% (16 h)	ABS	[21]
	Liver	HepG2	530 µg/mL	50% (72 h)	MTT	[20]
Glycyrrhizic acid	Prostate	LNCaP	8.5 mM	50% (48 h)	CCK-8	[42]
		DU 145	12.5 mM	50% (48 h)	CCK-8	[42]
	Lung	A549	1 mM	50% (72 h)	MTS	[40]
	Glioblastoma	U251	2 mM	28% (24 h), 75% (48 h), and 90% (72 h)	CCK-8	[41]
Glycyrrhetic acid	Stomach	AGS	125.2 µM	50% (48 h)	MTT	[103]
		BGC823	30 µM	65% (24 h)	MTT	[71]
		MKN-28	146.7 µM	50% (48 h)	MTT	[103]
		MKN-45	157 µM	50% (48 h)	MTT	[103]
		SGC7901	30 µM	46% (24 h)	MTT	[71]
		SGC7901	135.7 µM	50% (48 h)	MTT	[103]
	Colon	DLD-1	81.21 µM	50% (96 h)	SRB	[68]
		HCT 116	78.33 µM	50% (96 h)	SRB	[68]
		HCT-8	78.85 µM	50% (96 h)	SRB	[68]
		HT-29	80.09 µM	50% (96 h)	SRB	[68]
		SW480	86.80 µM	50% (96 h)	SRB	[75]
	Lung	A549	82.76 µM	50% (96 h)	SRB	[68]
		A549	165.7 µM	50% (24 h)	XTT	[73]
		NCI-H460	131.7 µM	50% (24 h)	XTT	[73]
	Prostrate	LNCaP	200 µM	35% (48 h)	MTT	[74]
		DU 145	200 µM	52% (48 h)	MTT	[74]
	Ovary	OVCAR-3	25 µM	24% (24 h), 42% (48 h), and 52% (72 h)	MTT	[69]
		SK-OV-3	25 µM	23% (24 h), 42% (48 h), and 51% (72 h)	MTT	[69]
	Melanoma	SK-MEL-28	30 µM	55% (48 h)	MTT	[35]
		SK-MEL-2	30 µM	50% (48 h)	MTT	[35]
		518A2	83.92 µM	50% (96 h)	SRB	[68]
	Thyroid	8505 C	86.50 µM	50% (96 h)	SRB	[75]
		SW1736	76.93 µM	50% (96 h)	SRB	[68]
	Cervix	SiHa	50 µM	58% (24 h)	MTT	[34]
	Liver	HepG2	80 µM	50% (72 h)	TBD	[39]
		HepG2	40 µM	50% (48 h)	MTT	[34]
	Submaxillary salivary gland	A-253	80.78 µM	50% (96 h)	SRB	[68]
	Skin	A-431	79.58 µM	50% (96 h)	SRB	[68]
	Pharynx	FaDu	84.55 µM	50% (96 h)	SRB	[75]
Breast	MCF7	84.70 µM	50% (96 h)	SRB	[68]	
Leukemia	HL-60	63.2 µM	50% (96 h)	SRB	[77]	

cont.

p.o.), and GA (580 mg/kg, p.o.) were 37 µg/mL, 42 µg/mL, 55 µg/mL, and 90 µg/mL, respectively [183]. More pharmacokinetic studies on licorice using different models should be carried out, and the maximum tolerated dose of licorice or pure compounds is also critical for licorice's clinical use. Also, whether the concentration of the compounds in a tumor microenvironment can

reach the doses used *in vitro* (due to the *in vitro* concentrations of some compounds used being too high, such as GL) needs to be considered further. Therefore, the evaluation of the *in vivo* anticancer effects of licorice might be much more significant. Although numerous proteins or genes can be affected by licorice compounds, the actual targets and mechanisms still remain un-

Table 1 Continued

Compounds	Cancer tissue/disease	Cancer cell	Concentration	Inhibition rate	Method	Ref.	
Isoliquiritigenin	Cervix	C-33 A	40 μ M	62% (24 h), 64% (48 h), and 72% (72 h)	MTT	[101]	
		Ca Ski	40 μ M	23% (24 h), 56% (48 h), and 56% (72 h)	MTT	[101]	
		HeLa	9.8 μ M	50% (48 h)	XTT	[99]	
		HeLa	40 μ M	42% (24 h), 36% (48 h), and 55% (72 h)	MTT	[101]	
		SiHa	40 μ M	32% (24 h), 38% (48 h), and 61% (72 h)	MTT	[101]	
			U14	97.56 μ M	about 61.57% (48 h)	MTT	[102]
	Breast	MCF7	10 μ M	50% (48 h)	MTS	[111]	
		MCF7	50 μ M	about 50% (72 h)	MTT	[112]	
		MCF7aro	5 μ M	about 65% (48 h)	MTT	[142]	
		MDA-MB-231	5 μ M	50% (48 h)	MTS	[111]	
		MDA-MB-231	25 μ M	about 50% (72 h)	MTT	[112]	
	Colon	CT26	60 μ M	about 40% (24 h) and 70% (72 h)	MTT	[105]	
		Colon 26	14.6 μ M	50% (48 h)	MTT	[106]	
		COLO 320DM	17.9 μ M	50% (72 h)	MTT	[106]	
		HCT 116	40 μ M	25% (48 h), 40% (72 h), and 50% (96 h)	MTT	[104]	
		HT-29	40 μ M	30% (24 h), 38% (48 h), and 42% (72 h)	MTT	[104]	
		RCN-9	19.5 μ M	50% (48 h)	MTT	[106]	
				C4-2	87 μ M	50% (24 h)	MTT
	Prostate	DU 145	11 μ M	50% (48 h)	TBD	[107]	
		DU 145	20 μ M	25% (24 h), 39% (48 h), and 56% (72 h)	MTT	[109]	
		LNCaP	13 μ M	50% (48 h)	TBD	[107]	
		LNCaP	100 μ M	62% (24 h)	MTT	[108]	
		MLL	5 μ M	11% (24 h), 41% (48 h), and 50% (72 h)	MTT	[109]	
				ARH-77	14.6 μ M	about 50% (48 h)	CCK-8
	Myeloma	CZ-1	13.9 μ M	about 50% (48 h)	CCK-8	[110]	
		MPC-11	4.4 μ M	about 50% (48 h)	CCK-8	[110]	
		RPMI 8226	9.1 μ M	about 50% (48 h)	CCK-8	[110]	
		SP2/0	22.9 μ M	about 50% (48 h)	CCK-8	[110]	
		U266	8.6 μ M	about 50% (48 h)	CCK-8	[110]	
				AGS	147.3 μ M	50% (48 h)	MTT
	Stomach	MKN-28	167.8 μ M	50% (48 h)	MTT	[103]	
		MKN-45	128.4 μ M	50% (48 h)	MTT	[103]	
		SGC7901	157.9 μ M	50% (48 h)	MTT	[103]	
				HSC-2	79 μ M	50% (24 h)	MTT
	Oral cavity	HSC-3	97 μ M	50% (24 h)	MTT	[124]	
				HepG2	156.1 μ M	about 50% (48 h)	MTT
	Liver	HepG2	41 μ M	about 50% (48 h)	XTT	[121]	
				A549	18.5 μ M	50% (72 h)	TBD
	Lung	A549	27.14 μ M	50% (24 h)	XTT	[115]	
				HL-60	58.5 μ M	about 86.7% (72 h)	MTT
	Leukemia	HL-60	22 μ M	50% (24 h)	MTT	[124]	
			Renca	39 μ M	about 30% (72 h)	ABS	[119]
Kindeg	Renca	39 μ M	about 30% (72 h)	ABS	[119]		
Submandibular gland	HSG	125 μ M	50% (24 h)	MTT	[124]		
Brain	U-87	40 μ M	20% (24 h), 53% (48 h), and 75% (72 h)	MTT	[118]		
Ovary	SK-OV-3	156.1 μ M	about 83.1% (24 h)	MTT	[117]		
Licochalcone A	Stomach	AGS	41.1 μ M	50% (48 h)	MTT	[103]	
		MKN-28	42 μ M	50% (48 h)	MTT	[103]	
		MKN-45	40.7 μ M	50% (48 h)	MTT	[103]	
		SGC7901	40.8 μ M	50% (48 h)	MTT	[103]	
	Liver	HepG2	10 μ M	54% (24 h)	MTT	[147]	
		Hep3B	10 μ M	40% (24 h)	MTT	[147]	
		SNU878	10 μ M	38% (24 h)	MTT	[147]	
	Ovary	OVCAR-3	15 μ M	68% (24 h)	MTT	[152]	
		SK-OV-3	15 μ M	61% (24 h)	MTT	[152]	
		SK-OV-3	13.5 μ M	about 50% (48 h)	SRB	[151]	
	Prostate	PC-3	25 μ M	80% (48 h) and 83% (72 h)	TBD	[149]	
		LNCaP	50 μ M	5.5% (48 h)	MTT	[148]	
	Colon	CT26	20 μ M	56.3% (24 h) and 74.3% (72 h)	MTT	[150]	
		HCT-15	10.1 μ M	about 50% (48 h)	SRB	[151]	
	Cervix	HeLa	50 μ M	17.4% (24 h)	MTT	[153]	
	Bladder	T24	100 μ M	54% (12 h), 64% (24 h), and 79% (48 h)	MTT	[167]	
	Lung	A549	14.3 μ M	about 50% (48 h)	SRB	[151]	
Skin	SK-MEL-2	7.9 μ M	about 50% (48 h)	SRB	[151]		

cont.

Table 1 Continued

Compounds	Cancer tissue/disease	Cancer cell	Concentration	Inhibition rate	Method	Ref.
Licochalcone B	Bladder	T24	60 μ M	25% (24 h), 55% (48 h), and 67% (72 h)	MTT	[167]
		EJ	60 μ M	50% (24 h), 65% (48 h), and 75% (72 h)	MTT	[167]
Licochalcone E	Colon	HCT-15	10.1 μ M	about 50% (48 h)	SRB	[151]
	Skin	SK-MEL-2	8.5 μ M	about 50% (48 h)	SRB	[151]
	Lung	A549	17.3 μ M	about 50% (48 h)	SRB	[151]
	Ovary	SK-OV-3	15.5 μ M	about 50% (48 h)	SRB	[151]
Liquiritigenin	Stomach	AGS	339.3 μ M	50% (48 h)	MTT	[103]
		MKN-28	314.7 μ M	50% (48 h)	MTT	[103]
		MKN-45	376.7 μ M	50% (48 h)	MTT	[103]
		SGC7901	358 μ M	50% (48 h)	MTT	[103]
	Cervix	HeLa	200 μ M	24% (24 h), 48% (48 h), and 65% (72 h)	MTT	[171]
	Liver	SMMC-7721	400 μ M	76% (48 h)	MTT	[170]
Isoangustone A	Prostrate	PC3	10 μ M	52% (24 h)	MTT	[176]
	Colon	SW480	6 μ M	40% (24 h)	MTT	[175]
Glabridin	Stomach	AGS	69.6 μ M	50% (48 h)	MTT	[103]
		MKN-28	61 μ M	50% (48 h)	MTT	[103]
		MKN-45	83.7 μ M	50% (48 h)	MTT	[103]
		SGC7901	84.2 μ M	50% (48 h)	MTT	[103]
Licoumarone	Lymphocyte	U-937	147 μ M	about 75% (16 h)	ABS	[21]
β -Hydroxy-DHP	Breast	MCF7	13 μ M	50% (72 h)	MTT	[28]

ABS: Alamar Blue assay; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-phenyl)-2 H-tetrazolium, inner salt assay; MCF7aro: stably transfected with human CYP19 cells; XTT: 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino)carbonyl]-2 H-tetrazolium hydroxide assay; TBD: trypan blue dye assay; SRB: Sulforhodamine B assay

Table 2 The anticancer properties of licorice compounds *in vivo*.

Compounds	Models	Treatments	Outcomes	Ref.
Methanol extracts of licorice	EAT-bearing mice	i. p., 500 μ g, 7 days	inhibition of growth of EAT cells and formation of ascites fluid by inhibition of angiogenesis	[30]
Aqueous extracts of licorice	EAT-bearing mice	i. p., 600 μ g, 7 days	inhibition of growth of EAT cells and formation of ascites fluid by inhibition of angiogenesis	[30]
Hexane/ethanol extracts of licorice	4 T1-injected female BALB/c mice	In drinking water, 5 mg/kg/day,	inhibiting the tumor volumes by reducing the expression of CDK2, CDK4, and PCNA	[27]
70% ethanol (volume, CH ₃ CH ₃ OH: H ₂ O = 70:30) extracts of licorice	MDA-MB-231 xenografted Balb/c mice	i. g., 2 mg/kg, once a day for 5 days, followed by further administration once a week for 44 days	blocking the tumor growth and tumor volume	[22]
95% ethanol (volume, CH ₃ CH ₃ OH: H ₂ O = 95:5) extracts of licorice	CT26 xenografted BALB/c mice	i. g., 0.5, 1, and 2 mg/kg, once a day for 15 days	inhibiting tumor growth by 38%, 57%, and 71%, respectively	[31]
Glycyrrhizic acid	Renca cells inject s. c. into BALB/c mice.	i. p., 50 mg/kg, once a day for a week	suppressing 35% of tumor weight and 60% of tumor volume by reducing angiogenesis	[46]
	ovariectomized mice models	p. o., diet containing 0.0625% wt of GA, two weeks	GA suppressed the endometrial cancer progress by inhibiting the expression of COX-2, TNF- α , and IL-1	[63]
	acetate-induced hyperproliferative activity in Wistar rats	p. o, 300 mg/kg, once a day for 5 days before i. p. of acetate	inhibition of ODC activity and DNA synthesis	[64]
	A549-bearing mice models	i. p., 50 mg/kg, once every other day for 8 weeks	inhibiting the tumor growth by reduction of TxA2 expression	[40]
	diethylnitrosamine-induced hepato tumor of BALB/c mice models	i. m., 2 mg/mouse, three times a week for 32 weeks	suppression of the mean number of liver tumors from 1.64 to 0.71 and reduction of the incidence rate of hepatic tumors from 64% to 21%	[67]
Glycyrrhetic acid	SGC7901 xenografted nude mice	s. c., 30 mg/kg, once every other day for 4 weeks	inhibition of tumor tissues growth and induced apoptosis by decreasing the expression of Bid	[71] cont.

clear. Thus, we suggest that more high throughput technologies, such as genomics, proteomics, biochip, and high-content screening, may be utilized to promote the explorative speed of the anticancer mechanisms of licorice [187, 188]. For example, by utilizing the oligonucleotide microarray analysis to screen 3360 genes

after treatment with 0.25 μ g/mL tanshinone IIA for 72 h in MCF7 cells, 41 genes were increased and 24 genes were decreased. Among these genes, the ADP-ribosyltransferase gene exhibited the maximum induction, thus indicating that the gene may be the main target [189]. Besides, through the use of frontal affinity

Table 2 Continued

Compounds	Models	Treatments	Outcomes	Ref.
Isoliquiritigenin	MDA-MB-231 xenografted nude mice	i. p., 50 and 100 mg/kg, three times a week for 5 weeks	decreasing the tumor weight about 43.1% and 62.3%, respectively, with the downregulation of the intratumoral PGE ₂ , 20-HETE, and p-Akt levels, while induction of intratumoral cleaved caspase-3 and cleaved PARP levels	[111]
	MDA-MB-231 implanted Balb/c mice	p. o., 10 mg/kg, 5 times a week for 5 weeks	remarkably inhibition of the number of lung surface metastases with decreasing the intratumoral levels of MMP-2 and MMP-9	[131]
	U14-implanted Kunming female mice model	p. o., 20 mg/kg, once a day for 10 days	inhibiting the tumor weight about 43.55% and enhancing the antitumor growth of CP from 35.57% to 65.66%	[102]
	B16-F0 cells (treated or untreated with 15 µg/mL ISL for 48 h) were inoculated s.c into C57BL/6 mice	10 days	inhibiting the tumor weight about 29.6%	[123]
	U266 xenografted SCID mice	i. p., 100 and 200 µg/kg, 20 days	suppressing the tumor volume about 47.56% and 64.55%, respectively	[110]
	MPC-11 xenografted BABL/C mice	i. p., 100 and 200 µg/kg, 15 days	inhibiting the tumor volume about 82.30% and 90.64%, respectively	[110]
	ACC-M xenografted BALB/c nude mice models	p. o., 0.5 g/kg or 1 g/kg, daily for 30 consecutive days	inhibiting the tumor growth by induction of the mTOR-dependent autophagic and apoptosis	[132]
	Renca xenografted BALB/c male mice models	i. p., 0.1, 0.5, 2, 10 mg/day, once a day for 10 days	decreasing 40.59%, 45.59%, 60.00%, and 68.23% of metastatic nodules in lungs, respectively, by suppressing the amount of VEGF and activating the immune system	[119]
	CT26 inoculated into BALB/c mice models,	p. o., 1 mg/kg, once a day for 15 days	suppressing the 52% of tumors growth, enhancing the antitumor growth effects of cisplatin, and alleviating the cisplatin-induced nephrotoxicity and hepatotoxicity by blocking the oxidative stress and intracellular ROS generation	[105]
	in the AOM-induced colonic aberrant crypt focus and cancer formation of ddY mice model	p. o., 15 ppm in drinking water, 4 weeks	exhibition of 37.3% inhibitory rate of the colonic aberrant crypt focus and cancer formation	[146]
Licochalcone A	CT26 cells inoculated into Balb/c mice	p. o., 1 mg/kg, once a day for 15 days	inhibited the growth of tumors by 49%	[150]
	AOM/DSS-induced colon carcinogenesis C57BL/6 mice	p. o., 5, 15, and 30 mg/kg, three times a week for 46 days	exhibition of 41%, 75%, and 98% inhibitory rate in cancer growth, respectively, and inhibition of the tumor metastasis with decreasing β-catenin expression and MMP-9 activity in cancer tissue	[165]
Licochalcone B	MB49 xenografted C57BL/6 mice model	i. t., 100 µL of LCB (160 µM) once every other day for 23 days	obviously inhibiting the tumor growth by inducing apoptosis	[167]
Liquiritigenin	H22-bearing mice models	i. g., 20 mg/kg, once a day for 15 days	exhibition of 49.3% of tumor growth inhibitory rate, reduction of the MDA content, and induction of apoptosis	[174]
	HeLa implanted nude mice	i. g., 40 mg/kg, once every other day for 28 days	exhibition of more than 50% inhibitory rate on the tumor growth, and inhibition of VEGF and MVD expressions	[173]
Isoangustone A	PC3 xenografted in BALB/c nude mice	i. p. 5 mg/kg, once a day for 8 weeks	reducing tumor volume and tumor weight about 70.0% and 53.6%, respectively, inhibiting about 58% of PCNA expression, and inducing G1/S phase arrest by decreasing p27 ^{kip1} expression	[176]
	SK-MEL-28-injected male BALB/c mice,	i. p., 2 or 10 mg/kg, once a day for 5 weeks	inhibiting the tumor volume and weight by decreasing the expression of PCNA, and inhibiting PI3 K, MKK4, and MKK7 activities without losing body weight	[177]
Glabridin	in SK-Hep-1 xenograft BALB/c nude mice	i. p., 10 mg/kg, three times a week	suppressing the tumor growth without statistically significant changes in body weight	[180]

chromatography with mass spectrometry detection, the erythropoietin-producing hepatocellular B2 inhibitor has been successfully identified [190]. Therefore, those research methods can also be performed in the future to study the targets and mechanisms of licorice compounds.

Licorice has been traditionally recognized as a "guide drug" (drugs that enhance the effectiveness and reduce the toxicity of other ingredients) and is added to most traditional and modern prescriptions [15, 191]. Basic *in vitro* and *in vivo* pharmacological studies indicate that the combined treatment of licorice compounds,

Compounds	Mechanisms						
	Cell cycle arrest	Apoptosis	Autophagy	Anti-metastasis	Anti-angiogenesis	Differentiation	Sensitization
Mixed extracts							Inhibition of mTOR signaling, induction of p53 and Bax, etc.
Glycyrrhizic acid							Inhibition of NF- κ B, E-selectin, TNF- α , and HMGB1, etc.
Glycyrrhetic acid							Inhibition of NF- κ B, PKC, and GSH, etc.
Isoliquiritigenin							Inhibition of NF- κ B, and JNK, etc.
Licochalcone A							Blockage of ERK, NF- κ B, and STAT3 signals, etc.
Licochalcone B							Inhibition of Bcl-2 and survivin, induction of Bax, etc.
Licochalcone E							Inhibition of DNA topoisomerase I, NF- κ B, and Ki67, etc.
Liquiritigenin							Retardation of Akt, activation of p53, production of ROS, etc.
Isoangustone A							Blockage of mTOR and JNK signaling, activation of DR4, etc.
Glabridin							Down-regulation of RhoA, FAK, Akt, and Src, etc.
Isoliquiritin							Down-regulation of tube formation, etc.
Licoricidin							Inhibition of uPA, MMP-9, and ICAM, etc.
Licocoumarone							Up-regulation of DNA fragmentation, etc.
Glycyrol							Induction of caspase-8, caspase-9, and Fas, etc.
β -hydroxy-DHP							Induction of Bcl-2 phosphorylation, etc.

Fig. 2 The anticancer properties and molecular mechanisms of the mixed extracts and purified compounds isolated from licorice. The left panel indicates the anticancer compounds from licorice, the middle panel indicates the impacts of each compound on anticancer studies (the highlighted boxes color means the relevant anticancer effects in the heading have been studied), and the right panel indicates the potential targets or mechanisms contributing to anticancer activities. (Color figure available online only.)

such as GA, ISLG, and LCA, with clinical chemotherapy drugs presents both synergistic antineoplastic effects and a reduction of the side effects of chemotherapeutics [34, 102, 105, 148]. GL also reverses cisplatin resistance in hepatocellular carcinoma cells [47]. Furthermore, GL pretreatment enhances UVB-induced apoptosis in melanoma cells, blocks UVB-induced skin tumor formation, and hinders ionizing radiation-induced tumor cell extravasation and lung metastasis [35, 49]. All of these findings indicate that a combined therapy may provide an optimal venue for licorice compounds in clinical application.

Among the purified compounds from licorice, the exploitation of the anticancer effects of GA may be much more compelling. First, GA is of high content and can easily be accessed from licorice with a spectrum of bioactivities [6, 97, 192]. Second, GA has been widely and successfully structure-modified to enhance its anticancer effects and other bioactivities [193–195]. For example, aminoalkyl-modified GA methyl esters successfully yield novel GA derivatives, which exhibit IC_{50} values between 0.6 and 3.0 μ M in 14 kinds of cancer cells, while maintaining an IC_{50} of GA of 80 μ M in those cancer cells [75]. Furthermore, GA has been widely utilized as a hepatic-targeting ligand in TDDS because of the abundant receptors for GA on the hepatocyte membrane [32, 96]. Numerous hepatic TDDSs have been developed, such as doxorubicin-loaded GA-modified alginate nanoparticles [96], doxorubicin-loaded GA-modified sulfated chitosan [94], and 5-fluorouracil-loaded GA-modified chitosan nanoparticles [93] among others. Those nanoparticles not only enhance the hepatic accumulation of chemotherapeutics to enhance the anticancer effects, but also decrease the side effects.

Acknowledgements

We greatly thank Dr. Xi-Wen Li from the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences for his useful comments. This work was supported by the Macao Science

and Technology Development Fund (074/2012/A3) and the Research Fund of University of Macau (MRG013/WYT/2013/ICMS, CPG2014-00012-ICMS, and MYRG2015-00101-ICMS-QRCM).

Conflict of Interest

The authors declare that they have no competing interests.

References

- Blumenthal M, Goldberg A, Brinckmann J, editors. Herbal medicine: expanded commission E monographs. Boston, MA: Integrative Medicine Communications; 2000
- Yang S. The Divine Farmer's Materia Medica: A Translation of the Shen Nong Ben Cao Jing. Boulder, CO: Blue Poppy Enterprises, Inc.; 1998
- Nomura T, Fukai T. Phenolic constituents of licorice (*Glycyrrhiza* species). In: Herz W, Kirby GW, Moore RE, Steglich W, Tamm C, editors. Fortschritte der Chemie organischer Naturstoffe/Progress in the Chemistry of Organic Natural Products, Vol. 73. Vienna: Springer; 1998: 1–140
- Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. *Yakugaku Zasshi* 2000; 120: 849–862
- Fujita T, Sezik E, Tabata M, Yesilada E, Honda G, Takeda Y, Tanaka T, Takaishi Y. Traditional medicine in Turkey VII. Folk medicine in middle and west Black Sea regions. *Econ Bot* 1995; 49: 406–422
- Asl MN, Hosseinzadeh H. Review of pharmacological effects of *Glycyrrhiza* sp. and its bioactive compounds. *Phytother Res* 2008; 22: 709–724
- Wang ZY, Nixon DW. Licorice and cancer. *Nutr Cancer* 2001; 39: 1–11
- Nomura T, Fukai T, Akiyama T. Chemistry of phenolic compounds of licorice (*Glycyrrhiza* species) and their estrogenic and cytotoxic activities. *Pure Appl Chem* 2002; 74: 1199–1206
- Zhang Q, Ye M. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). *J Chromatogr A* 2009; 13: 1954–1969
- Ong ES, Len SM. Pressurized hot water extraction of berberine, baicalin and glycyrrhizin in medicinal plants. *Anal Chim Acta* 2003; 482: 81–89
- Li BQ, Wang HB, Li XY, Cheng X. Study on combined extraction of flavonoids and glycyrrhizic acid from *Glycyrrhiza* by using ultrasonic assisted method. *SDJ Tradit Chin Med* 2005; 24: 38–40

- 12 Ong ES. Chemical assay of glycyrrhizin in medicinal plants by pressurized liquid extraction (PLE) with capillary zone electrophoresis (CZE). *J Sep Sci* 2002; 25: 825–831
- 13 Wang HB, Zhou ZB, Luo F, Yang L. Study on extraction method of flavonoids from *Glycyrrhiza* and its anti-oxida activity. *LSZ Med and Mater Med Res* 2008; 19: 2106–2107
- 14 Cui YM, Yu LJ, Ao MZ, Yang Y, Hu J. Studies on flavonoids extraction technology from *Glycyrrhiza inflata* and their bacteriostatic activities. *J Chin Med Mater* 2006; 29: 838–841
- 15 Commission CP. Pharmacopoeia of the People's Republic of China, Part 1 (2010). Beijing: China Medical Science Press; 2010
- 16 Shin EM, Kim S, Merfort I, Kim YS. Glycyrol induces apoptosis in human Jurkat T cell lymphocytes via the Fas-FasL/caspase-8 pathway. *Planta Med* 2011; 77: 242–247
- 17 Shimizu N, Tomoda M, Takada K, Gonda R. The core structure and immunological activities of glycyrrhizin UA, the main polysaccharide from the root of *Glycyrrhiza uralensis*. *Chem Pharm Bull (Tokyo)* 1992; 40: 2125–2128
- 18 Yang G, Yu Y. Immunopotentiating effect of traditional Chinese drugs—ginsenoside and glycyrrhiza polysaccharide. *Proc Chin Acad Med Sci Peking Union Med Coll* 1990; 5: 188–193
- 19 Jo EH, Hong HD, Ahn NC, Jung JW, Yang SR, Park JS, Kim SH, Lee YS, Kang KS. Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (*Glycyrrhiza uralensis* Fisch) in MCF-7 human breast cancer cell. *J Agric Food Chem* 2004; 52: 1715–1719
- 20 Popovich DG, Yeo SY, Zhang W. Ginseng (*Panax quinquefolius*) and licorice (*Glycyrrhiza uralensis*) root extract combinations increase hepatocarcinoma cell (Hep-G2) viability. *Evid Based Complement Alternat Med* 2011; 2011: 408273
- 21 Watanabe M, Hayakawa S, Isemura M, Kumazawa S, Nakayama T, Mori C, Kawakami T. Identification of licocoumarone as an apoptosis-inducing component in licorice. *Biol Pharm Bull* 2002; 25: 1388–1390
- 22 Lee SK, Park KK, Park JH, Lim SS, Chung WY. The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction. *Phytother Res* 2013; 27: 1776–1783
- 23 Yo YT, Shieh GS, Hsu KF, Wu CL, Shiau AL. Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. *J Agric Food Chem* 2009; 57: 8266–8273
- 24 Park SY, Kim EJ, Choi HJ, Seon MR, Lim SS, Kang YH, Choi MS, Lee KW, Park Y, Han J. Anti-carcinogenic effects of non-polar components containing licochalcone A in roasted licorice root. *Nutr Res Pract* 2014; 8: 257–266
- 25 Chung WT, Lee SH, Kim JD, Sung NS, Hwang B, Lee SY, Yu CY, Lee HY. Effect of the extracts from *Glycyrrhiza uralensis* Fisch on the growth characteristics of human cell lines: anti-tumor and immune activation activities. *Cytotechnology* 2001; 37: 55–64
- 26 Jo EH, Kim SH, Ra JC, Kim SR, Cho SD, Jung JW, Yang SR, Park JS, Hwang JW, Aruoma OI, Kim TY, Lee YS, Kang KS. Chemopreventive properties of the ethanol extract of chinese licorice (*Glycyrrhiza uralensis*) root: induction of apoptosis and G1 cell cycle arrest in MCF-7 human breast cancer cells. *Cancer Lett* 2005; 230: 239–247
- 27 Seon MR, Park SY, Kwon SJ, Lim SS, Choi HJ, Park H, Lim do Y, Kim JS, Lee CH, Kim J, Park JH. Hexane/ethanol extract of *Glycyrrhiza uralensis* and its active compound isoangustone A induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells. *J Nutr Biochem* 2012; 23: 85–92
- 28 Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, Gallo MA, DiPaola RS. Novel polyphenol molecule isolated from licorice root (*Glycyrrhiza glabra*) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. *J Agric Food Chem* 2002; 50: 677–684
- 29 Seon MR, Lim SS, Choi HJ, Park SY, Cho HJ, Kim JK, Kim J, Kwon DY, Park JH. Isoangustone A present in hexane/ethanol extract of *Glycyrrhiza uralensis* induces apoptosis in DU145 human prostate cancer cells via the activation of DR4 and intrinsic apoptosis pathway. *Mol Nutr Food Res* 2010; 54: 1329–1339
- 30 Sheela ML, Ramakrishna MK, Salimath BP. Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibited by *Glycyrrhiza glabra*. *Int Immunopharmacol* 2006; 6: 494–498
- 31 Lee CK, Park KK, Lim SS, Park JH, Chung WY. Effects of the licorice extract against tumor growth and cisplatin-induced toxicity in a mouse xenograft model of colon cancer. *Biol Pharm Bull* 2007; 30: 2191–2195
- 32 Negishi M, Irie A, Nagata N, Ichikawa A. Specific binding of glycyrrhetic acid to the rat liver membrane. *Biochim Biophys Acta* 1991; 1066: 77–82
- 33 Ismail MG, Stanca C, Ha HR, Renner EL, Meier PJ, Kullak-Ublick GA. Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. *Hepatol Res* 2003; 26: 343–347
- 34 Lee CS, Kim YJ, Lee MS, Han ES, Lee SJ. 18 β -Glycyrrhetic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity. *Life Sci* 2008; 83: 481–489
- 35 Rossi T, Benassi L, Magnoni C, Ruberto AI, Coppi A, Baggio G. Effects of glycyrrhizin on UVB-irradiated melanoma cells. *In Vivo* 2005; 19: 319–322
- 36 Lee J, Jung E, Park J, Jung K, Park E, Kim J, Hong S, Park J, Park S, Lee S, Park D. Glycyrrhizin induces melanogenesis by elevating a cAMP level in b16 melanoma cells. *J Invest Dermatol* 2005; 124: 405–411
- 37 Chueh FS, Hsiao YT, Chang SJ, Wu PP, Yang JS, Lin JJ, Chung JG, Lai TY. Glycyrrhizic acid induces apoptosis in WEHI-3 mouse leukemia cells through the caspase- and mitochondria-dependent pathways. *Oncol Rep* 2012; 28: 2069–2076
- 38 He SQ, Gao M, Fu YF, Zhang YN. Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling. *Int J Clin Exp Pathol* 2015; 8: 5175–5181
- 39 Satomi Y, Nishino H, Shibata S. Glycyrrhetic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2. *Anticancer Res* 2005; 25: 4043–4047
- 40 Huang RY, Chu YL, Jiang ZB, Chen XM, Zhang X, Zeng X. Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase. *Cell Physiol Biochem* 2014; 33: 375–388
- 41 Li S, Zhu JH, Cao LP, Sun Q, Liu HD, Li JS, Hang CH. Growth inhibitory *in vitro* effects of glycyrrhizic acid in U251 glioblastoma cell line. *Neuro Sci* 2014; 35: 1115–1120
- 42 Thiruganham S, Xu L, Ramaswamy K, Gnanasekar M. Glycyrrhizin induces apoptosis in prostate cancer cell lines DU-145 and LNCaP. *Oncol Rep* 2008; 20: 1387–1392
- 43 Rossi T, Castelli M, Zandomeneghi G, Ruberto A, Benassi L, Magnoni C, Santachiara S, Baggio G. Selectivity of action of glycyrrhizin derivatives on the growth of MCF-7 and HEP-2 cells. *Anticancer Res* 2003; 23: 3813–3818
- 44 Kobayashi M, Fujita K, Katakura T, Utsunomiya T, Pollard RB, Suzuki F. Inhibitory effect of glycyrrhizin on experimental pulmonary metastasis in mice inoculated with B16 melanoma. *Anticancer Res* 2002; 22: 4053–4058
- 45 Kobayashi S, Miyamoto T, Kimura I, Kimura M. Inhibitory effect of isoliquiritin, a compound in licorice root, on angiogenesis *in vivo* and tube formation *in vitro*. *Biol Pharm Bull* 1995; 18: 1382–1386
- 46 Kim KJ, Choi JS, Kim KW, Jeong JW. The anti-angiogenic activities of glycyrrhizic acid in tumor progression. *Phytother Res* 2013; 27: 841–846
- 47 Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. *Int J Oncol* 2007; 31: 1465–1472
- 48 Sun MF, Chang TT, Chang KW, Huang HJ, Chen HY, Tsai FJ, Lin JG, Chen CY. Blocking the DNA repair system by traditional Chinese medicine? *J Biomed Struct Dyn* 2011; 28: 895–906
- 49 Cherng JM, Tsai KD, Yu YW, Lin JC. Molecular mechanisms underlying chemopreventive activities of glycyrrhizic acid against UVB-radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. *Radiat Res* 2011; 176: 177–186
- 50 Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. *J Cell Biol* 2004; 164: 441–449
- 51 Shotorhani SS, Su ZL, Xu HX. Toll-like receptors are potential therapeutic targets in rheumatoid arthritis. *World J Biol Chem* 2011; 2: 167–172
- 52 Smolarczyk R, Cichon T, Matuszczak S, Mitrus I, Lesiak M, Kobusinska M, Kamysz W, Jarosz M, Sieron A, Szala S. The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. *Arch Immunol Ther Exp (Warsz)* 2012; 60: 391–399
- 53 Schlueter C, Weber H, Meyer B, Rogalla P, Rösler K, Hauke S, Bullerdiek J. Angiogenic signaling through hypoxia: HMGB1: an angiogenic switch molecule. *Am J Pathol* 2005; 166: 1259–1263
- 54 Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuglio L, Musco G, Bianchi ME. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. *Chem Biol* 2007; 14: 431–441
- 55 Gong G, Xiang L, Yuan L, Hu L, Wu W, Cai L, Yin L, Dong H. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ische-

- mia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats. *PLoS One* 2014; 9: e89450
- 56 Chung JG, Chung HL, Lin WC, Wang HH, Yeh CC, Hung CF, Li YC. Inhibition of N-acetyltransferase activity and DNA-2-aminofluorene adducts by glycyrrhizic acid in human colon tumour cells. *Food Chem Toxicol* 2000; 38: 163–172
 - 57 Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. *Cancer Res* 1987; 47: 1466–1469
 - 58 Kirilin WG, Trinidad A, Yerokun T, Ogolla F, Ferguson RJ, Andrews AF, Brady PK, Hein DW. Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosol. *Cancer Res* 1989; 49: 2448–2454
 - 59 Umemura T, Tokumo K, Sirma H, Gebhardt R, Poirier MC, Williams GM. Dose response effects of 2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver. *Cancer Lett* 1993; 73: 1–10
 - 60 Shi L, Tang C, Yin C. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma. *Biomaterials* 2012; 33: 7594–7604
 - 61 Lin A, Chen J, Liu Y, Deng S, Wu Z, Huang Y, Ping Q. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. *Drug Dev Ind Pharm* 2009; 35: 1348–1355
 - 62 Lin A, Liu Y, Huang Y, Sun J, Wu Z, Zhang X, Ping Q. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. *Int J Pharm* 2008; 359: 247–253
 - 63 Niwa K, Lian Z, Onogi K, Yun W, Tang L, Mori H, Tamaya T. Preventive effects of glycyrrhizin on estrogen-related endometrial carcinogenesis in mice. *Oncol Rep* 2007; 17: 617–622
 - 64 Rahman S, Sultana S. Chemopreventive activity of glycyrrhizin on lead acetate mediated hepatic oxidative stress and its hyperproliferative activity in Wistar rats. *Chem Biol Interact* 2006; 160: 61–69
 - 65 Rahman S, Sultana S. Glycyrrhizin exhibits potential chemopreventive activity on 12-O-tetradecanoyl phorbol-13-acetate-induced cutaneous oxidative stress and tumor promotion in Swiss albino mice. *J Enzyme Inhib Med Chem* 2007; 22: 363–369
 - 66 Agarwal R, Wang ZY, Mukhtar H. Inhibition of mouse skin tumor-initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water. *Nutr Cancer* 1991; 15: 187–193
 - 67 Shiota G, Harada K, Ishida M, Tomie Y, Okubo M, Katayama S, Ito H, Kawasaki H. Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. *Carcinogenesis* 1999; 20: 59–63
 - 68 Csuk R, Schwarz S, Siewert B, Kluge R, Ströhl D. Synthesis and antitumor activity of ring A modified glycyrrhetic acid derivatives. *Eur J Med Chem* 2011; 46: 5356–5369
 - 69 Yang JC, Myung SC, Kim W, Lee CS. 18 β -Glycyrrhetic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathway. *Mol Cell Biochem* 2012; 370: 209–219
 - 70 Lee CS, Yang JC, Kim YJ, Jang ER, Kim W, Myung SC. 18 β -Glycyrrhetic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines. *Eur J Pharmacol* 2010; 649: 354–361
 - 71 Lin D, Zhong W, Li J, Zhang B, Song G, Hu T. Involvement of BID translocation in glycyrrhetic acid and 11-deoxy glycyrrhetic acid-induced attenuation of gastric cancer growth. *Nutr Cancer* 2014; 66: 463–473
 - 72 Luo HL, Zhang ZL, Wu QN, Huang MS, Wei H, Zhang DF, Yang F. 18 β -Glycyrrhetic acid-induced apoptosis and relation with intracellular Ca²⁺ release in human breast carcinoma cells. *Chinese-German J Clin Oncol* 2004; 3: 137–140
 - 73 Song J, Ko HS, Sohn EJ, Kim B, Kim JH, Kim HJ, Kim C, Kim JE, Kim SH. Inhibition of protein kinase C α / β and activation of c-Jun NH₂-terminal kinase mediate glycyrrhetic acid induced apoptosis in non-small cell lung cancer NCI-H460 cells. *Bioorg Med Chem Lett* 2014; 24: 1188–1191
 - 74 Shetty AV, Thirugnanam S, Dakshinamoorthy G, Samykutty A, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Gnanasekar M. 18 α -glycyrrhetic acid targets prostate cancer cells by down-regulating inflammation-related genes. *Int J Oncol* 2011; 39: 635–640
 - 75 Csuk R, Schwarz S, Kluge R, Ströhl D. Synthesis and biological activity of some antitumor active derivatives from glycyrrhetic acid. *Eur J Med Chem* 2010; 45: 5718–5723
 - 76 Lin KW, Huang AM, Hour TC, Yang SC, Pu YS, Lin CN. 18 β -glycyrrhetic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells. *Bioorg Med Chem* 2011; 19: 4274–4285
 - 77 Liu D, Song D, Guo G, Wang R, Lv J, Jing Y, Zhao L. The synthesis of 18 β -ta-glycyrrhetic acid derivatives which have increased antiproliferative and apoptotic effects in leukemia cells. *Bioorg Med Chem* 2007; 15: 5432–5439
 - 78 Yu T, Yamaguchi H, Noshita T, Kidachi Y, Umetsu H, Ryoyama K. Selective cytotoxicity of glycyrrhetic acid against tumorigenic r/m HM-SFME-1 cells: potential involvement of H-Ras downregulation. *Toxicol Lett* 2010; 192: 425–430
 - 79 Yamaguchi H, Yu T, Kidachi Y, Akitaya T, Yoshida K, Kamiie K, Noshita T, Umetsu H, Ryoyama K. Selective toxicity of glycyrrhetic acid against tumorigenic r/m HM-SFME-1 cells is potentially attributed to downregulation of glutathione. *Biochimie* 2011; 93: 1172–1178
 - 80 Yamaguchi H, Noshita T, Yu T, Kidachi Y, Kamiie K, Umetsu H, Ryoyama K. Novel effects of glycyrrhetic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity. *Eur J Med Chem* 2010; 45: 2943–2948
 - 81 Sharma G, Kar S, Palit S, Das PK. 18 β -Glycyrrhetic acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast cancer MCF-7 cells. *J Cell Physiol* 2012; 227: 1923–1931
 - 82 Zhu J, Chen M, Chen N, Ma A, Zhu C, Zhao R, Jiang M, Zhou J, Ye L, Fu H, Zhang X. Glycyrrhetic acid induces G1 phase cell cycle arrest in human nonsmall cell lung cancer cells through endoplasmic reticulum stress pathway. *Int J Oncol* 2015; 46: 981–988
 - 83 Tang ZH, Li T, Chang LL, Zhu H, Tong YG, Chen XP, Wang YT, Lu JJ. Glycyrrhetic acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells. *J Agric Food Chem* 2014; 62: 11910–11916
 - 84 Hibasami H, Iwase H, Yoshioka K, Takahashi H. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelocytic leukemia and stomach cancer cells. *Int J Mol Med* 2006; 17: 215–219
 - 85 Jayasooriya RG, Dilshara MG, Park SR, Choi YH, Hyun JW, Chang WY, Kim GY. 18 β -Glycyrrhetic acid suppresses TNF- α induced matrix metalloproteinase-9 and vascular endothelial growth factor by suppressing the Akt-dependent NF- κ B pathway. *Toxicol In Vitro* 2014; 28: 751–758
 - 86 Wang XF, Zhou QM, Lu YY, Zhang H, Huang S, Su SB. Glycyrrhetic acid potentially suppresses breast cancer invasion and metastasis by impairing the p38 MAPK-AP1 signaling axis. *Expert Opin Ther Targets* 2015; 19: 577–587
 - 87 Kitagawa S, Nabekura T, Kamiyama S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. *J Pharm Pharmacol* 2004; 56: 1001–1005
 - 88 Yamaguchi H, Kidachi Y, Kamiie K, Noshita T, Umetsu H, Ryoyama K. Glycyrrhetic acid induces anoikis-like death and cytoskeletal disruption in the central nervous system tumorigenic cells. *Biol Pharm Bull* 2010; 33: 321–324
 - 89 Huang R, Li M, Hsin M, Underwood M, Ma L, Mok T, Warner T, Chen G. 4-Methylnitrosamino-1- β -pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A₂ and its receptor. *Oncogene* 2010; 30: 106–116
 - 90 Kuang P, Zhao W, Su W, Zhang Z, Zhang L, Liu J, Ren G, Yin Z, Wang X. 18 β -Glycyrrhetic acid inhibits hepatocellular carcinoma development by reversing hepatic stellate cell-mediated immunosuppression in mice. *Int J Cancer* 2013; 132: 1831–1841
 - 91 Endo S, Matsunaga T, Soda M, Tajima K, Zhao HT, El-Kabbani O, Hara A. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. *Biol Pharm Bull* 2010; 33: 886–890
 - 92 Zhang C, Wang W, Liu T, Wu Y, Guo H, Wang P, Tian Q, Wang Y, Yuan Z. Doxorubicin-loaded glycyrrhetic acid-modified alginate nanoparticles for liver tumor chemotherapy. *Biomaterials* 2012; 33: 2187–2196
 - 93 Cheng M, Gao X, Wang Y, Chen H, He B, Xu H, Li Y, Han J, Zhang Z. Synthesis of glycyrrhetic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics *in vitro* and *in vivo*. *Mar Drugs* 2013; 11: 3517–3536
 - 94 Tian Q, Wang XH, Wang W, Zhang CN, Wang P, Yuan Z. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetic acid. *Nanomedicine* 2012; 8: 870–879
 - 95 Wang ZY, Agarwal R, Zhou ZC, Bickers DR, Mukhtar H. Inhibition of mutagenicity in *Salmonella typhimurium* and skin tumor initiating and tumor promoting activities in SENCAR mice by glycyrrhetic acid: comparison of 18 α - and 18 β -stereoisomers. *Carcinogenesis* 1991; 12: 187–192

- 96 Zhang C, Wang W, Liu T, Wu Y, Guo H, Wang P, Tian Q, Wang Y, Yuan Z. Doxorubicin-loaded glycyrrhetic acid-modified alginate nanoparticles for liver tumor chemotherapy. *Biomaterials* 2012; 33: 2187–2196
- 97 Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, Bielenberg J. Antiviral effects of *Glycyrrhiza* species. *Phytother Res* 2008; 22: 141–148
- 98 Gupta VK, Fatima A, Faridi U, Negi AS, Shanker K, Kumar J, Rahuja N, Luqman S, Sisodia BS, Saikia D. Antimicrobial potential of *Glycyrrhiza glabra* roots. *J Ethnopharmacol* 2008; 116: 377–380
- 99 Hsu YL, Chia CC, Chen PJ, Huang SE, Huang SC, Kuo PL. Shallot and licorice constituent isoliquiritigenin arrests cell cycle progression and induces apoptosis through the induction of ATM/p53 and initiation of the mitochondrial system in human cervical carcinoma HeLa cells. *Mol Nutr Food Res* 2009; 53: 826–835
- 100 Yuan X, Zhang B, Chen N, Chen XY, Liu LL, Zheng QS, Wang ZP. Isoliquiritigenin treatment induces apoptosis by increasing intracellular ROS levels in HeLa cells. *J Asian Nat Prod Res* 2012; 14: 789–798
- 101 Hirschaud F, Hermetet F, Ablise M, Fauconnet S, Vuitton DA, Pretet JL, Mougin C. Isoliquiritigenin induces caspase-dependent apoptosis via downregulation of HPV16 E6 expression in cervical cancer Ca ski cells. *Planta Med* 2013; 79: 1628–1635
- 102 Zhao H, Yuan X, Li D, Chen H, Jiang J, Wang Z, Sun X, Zheng Q. Isoliquiritigenin enhances the antitumor activity and decreases the genotoxic effect of cyclophosphamide. *Molecules* 2013; 18: 8786–8798
- 103 Xiao XY, Hao M, Yang XY, Ba Q, Li M, Ni SJ, Wang LS, Du X. Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. *Cancer Lett* 2011; 302: 69–75
- 104 Auyeung KK, Ko JK. Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. *Invest New Drugs* 2010; 28: 1–13
- 105 Lee CK, Son SH, Park KK, Park JHY, Lim SS, Chung WY. Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. *J Pharmacol Sci* 2008; 106: 444–451
- 106 Takahashi T, Takasuka N, Iigo M, Baba M, Nishino H, Tsuda H, Okuyama T. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. *Cancer Sci* 2004; 95: 448–453
- 107 Kanazawa M, Satomi Y, Mizutani Y, Ukimura O, Kawauchi A, Sakai T, Baba M, Okuyama T, Nishino H, Miki T. Isoliquiritigenin inhibits the growth of prostate cancer. *Eur Urol* 2003; 43: 580–586
- 108 Zhang X, Yeung ED, Wang J, Panzhinskiy EE, Tong C, Li W, Li J. Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells. *Clin Exp Pharmacol Physiol* 2010; 37: 841–847
- 109 Jung JI, Lim SS, Choi HJ, Cho HJ, Shin HK, Kim EJ, Chung WY, Park KK, Park JH. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. *J Nutr Biochem* 2006; 17: 689–696
- 110 Chen X, Wu Y, Jiang Y, Zhou Y, Wang Y, Yao Y, Yi C, Gou L, Yang J. Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling. *J Mol Med (Berl)* 2012; 90: 1311–1319
- 111 Li Y, Zhao H, Wang Y, Zheng H, Yu W, Chai H, Zhang J, Falck JR, Guo AM, Yue J, Peng R, Yang J. Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3 K/Akt in human breast cancer. *Toxicol Appl Pharmacol* 2013; 272: 37–48
- 112 Wang KL, Hsia SM, Chan CJ, Chang FY, Huang CY, Bau DT, Wang PS. Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. *Expert Opin Ther Targets* 2013; 17: 337–349
- 113 Li D, Wang Z, Chen H, Wang J, Zheng Q, Shang J, Li J. Isoliquiritigenin induces monocytic differentiation of HL-60 cells. *Free Radic Biol Med* 2009; 46: 731–736
- 114 Li T, Satomi Y, Katoh D, Shimada J, Baba M, Okuyama T, Nishino H, Kitamura N. Induction of cell cycle arrest and p21(CIP1/WAF1) expression in human lung cancer cells by isoliquiritigenin. *Cancer Lett* 2004; 207: 27–35
- 115 Hsu YL, Kuo PL, Chiang LC, Lin CC. Isoliquiritigenin inhibits the proliferation and induces the apoptosis of human non-small cell lung cancer A549 cells. *Clin Exp Pharmacol Physiol* 2004; 31: 414–418
- 116 Jung SK, Lee MH, Lim do Y, Kim JE, Singh P, Lee SY, Jeong CH, Lim TG, Chen H, Chi YI, Kundu JK, Lee NH, Lee CC, Cho YY, Bode AM, Lee KW, Dong Z. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790 M mutant EGFR. *J Biol Chem* 2014; 289: 35839–35848
- 117 Yuan X, Yu B, Wang Y, Jiang J, Liu L, Zhao H, Qi W, Zheng Q. Involvement of endoplasmic reticulum stress in isoliquiritigenin-induced SKOV-3 cell apoptosis. *Recent Pat Anticancer Drug Discov* 2013; 8: 191–199
- 118 Zhou GS, Song LJ, Yang B. Isoliquiritigenin inhibits proliferation and induces apoptosis of U87 human glioma cells *in vitro*. *Mol Med Rep* 2013; 7: 531–536
- 119 Yamazaki S, Morita T, Endo H, Hamamoto T, Baba M, Joichi Y, Kaneko S, Okada Y, Okuyama T, Nishino H, Tokue A. Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. *Cancer Lett* 2002; 183: 23–30
- 120 Sun C, Zhang H, Ma XF, Zhou X, Gan L, Liu YY, Wang ZH. Isoliquiritigenin enhances radiosensitivity of HepG2 cells via disturbance of redox status. *Cell Biochem Biophys* 2013; 65: 433–444
- 121 Hsu YL, Kuo PL, Lin LT, Lin CC. Isoliquiritigenin inhibits cell proliferation and induces apoptosis in human hepatoma cells. *Planta Med* 2005; 71: 130–134
- 122 Hsu YL, Kuo PL, Lin CC. Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. *Life Sci* 2005; 77: 279–292
- 123 Chen X, Zhang B, Yuan X, Yang F, Liu J, Zhao H, Liu L, Wang Y, Wang Z, Zheng Q. Isoliquiritigenin-induced differentiation in mouse melanoma B16F0 cell line. *Oxid Med Cell Longev* 2012; 12: 1–12
- 124 Chowdhury SA, Kishino K, Satoh R, Hashimoto K, Kikuchi H, Nishikawa H, Shirataki Y, Sakagami H. Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids. *Anticancer Res* 2005; 25: 2055–2063
- 125 Kim DC, Ramachandran S, Baek SH, Kwon SH, Kwon KY, Cha SD, Bae I, Cho CH. Induction of growth inhibition and apoptosis in human uterine leiomyoma cells by isoliquiritigenin. *Reprod Sci* 2008; 15: 552–558
- 126 Park I, Park KK, Park JHY, Chung WY. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. *Cancer Lett* 2009; 277: 174–181
- 127 Lee CS, Kim YJ, Lee MS, Han ES, Lee SJ. 18Beta-glycyrrhetic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity. *Life Sci* 2008; 83: 481–489
- 128 Lee YM, Lim do Y, Choi HJ, Jung JI, Chung WY, Park JH. Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin. *J Med Food* 2009; 12: 8–14
- 129 Takahashi T, Baba M, Nishino H, Okuyama T. Cyclooxygenase-2 plays a suppressive role for induction of apoptosis in isoliquiritigenin-treated mouse colon cancer cells. *Cancer Lett* 2006; 231: 319–325
- 130 Yoshida T, Horinaka M, Takara M, Tsuchihashi M, Mukai N, Wakada M, Sakai T. Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. *Environ Health Prev Med* 2008; 13: 281–287
- 131 Zheng H, Li Y, Wang Y, Zhao H, Zhang J, Chai H, Tang T, Yue J, Guo AM, Yang J. Downregulation of COX-2 and CYP 4 A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis-resistance, migration and invasion. *Toxicol Appl Pharmacol* 2014; 280: 10–20
- 132 Chen G, Hu X, Zhang W, Xu N, Wang FQ, Jia J, Zhang WF, Sun ZJ, Zhao YF. Mammalian target of rapamycin regulates isoliquiritigenin-induced autophagic and apoptotic cell death in adenoid cystic carcinoma cells. *Apoptosis* 2012; 17: 90–101
- 133 Ma J, Fu NY, Pang DB, Wu WY, Xu AL. Apoptosis induced by isoliquiritigenin in human gastric cancer MGC-803 cells. *Planta Med* 2001; 67: 754–757
- 134 Iwashita K, Kobori M, Yamaki K, Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. *Biosci Biotechnol Biochem* 2000; 64: 1813–1820
- 135 Chen H, Zhang B, Yao Y, Chen N, Chen X, Tian H, Wang Z, Zheng Q. NADPH oxidase-derived reactive oxygen species are involved in the HL-60 cell monocytic differentiation induced by isoliquiritigenin. *Molecules* 2012; 17: 13424–13438
- 136 Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, Park JH. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. *J Nutr Biochem* 2009; 20: 663–676
- 137 Kumar S, Sharma A, Madan B, Singhal V, Ghosh B. Isoliquiritigenin inhibits IκappaB kinase activity and ROS generation to block TNF-alpha

- induced expression of cell adhesion molecules on human endothelial cells. *Biochem Pharmacol* 2007; 73: 1602–1612
- 138 *Kwon HM, Choi YJ, Choi JS, Kang SW, Bae JY, Kang IJ, Jun JG, Lee SS, Lim SS, Kang YH.* Blockade of cytokine-induced endothelial cell adhesion molecule expression by licorice isoliquiritigenin through NF- κ B signal disruption. *Exp Biol Med* 2007; 232: 235–245
- 139 *Kimura M, Kimura I, Luo B, Kobayashi S.* Antiinflammatory effect of Japanese-Sino medicine 'Keishi-ka-jutsu-bu-to' and its component drugs on adjuvant air pouch granuloma of mice. *Phytother Res* 1991; 5: 195–200
- 140 *Kang SW, Choi JS, Choi YJ, Bae JY, Li J, Kim DS, Kim JL, Shin SY, Lee YJ, Kwon IS, Kang YH.* Licorice isoliquiritigenin dampens angiogenic activity via inhibition of MAPK-responsive signaling pathways leading to induction of matrix metalloproteinases. *J Nutr Biochem* 2010; 21: 55–65
- 141 *Lee KM, Abel J, Ko Y, Harth V, Park WY, Seo JS, Yoo KY, Choi JY, Shin A, Ahn SH.* Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. *Br J Cancer* 2003; 88: 675–678
- 142 *Ye L, Gho WM, Chan FL, Chen S, Leung LK.* Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase. *Int J Cancer* 2009; 124: 1028–1036
- 143 *Wong TY, Lin SM, Poon CH, Leung LK.* The licorice flavonoid isoliquiritigenin reduces DNA-binding activity of AhR in MCF-7 cells. *Chem Biol Interact* 2014; 221: 70–76
- 144 *Wang N, Wang Z, Wang Y, Xie X, Shen J, Peng C, You J, Peng F, Tang H, Guan X, Chen J.* Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation. *Oncotarget* 2015; 6: 9854–9876
- 145 *Jung JI, Chung E, Seon MR, Shin HK, Kim EJ, Lim SS, Chung WY, Park KK, Park JH.* Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. *Biofactors* 2006; 28: 159–168
- 146 *Baba M, Asano R, Takigami I, Takahashi T, Ohmura M, Okada Y, Sugimoto H, Arika T, Nishino H, Okuyama T.* Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. *Biol Pharm Bull* 2002; 25: 247–250
- 147 *Choi AY, Choi JH, Hwang KY, Jeong YJ, Choe W, Yoon KS, Ha J, Kim SS, Youn JH, Yeo EJ, Kang I.* Licochalcone A induces apoptosis through endoplasmic reticulum stress via a phospholipase Cgamma1-, Ca-, and reactive oxygen species-dependent pathway in HepG2 human hepatocellular carcinoma cells. *Apoptosis* 2013; 19: 682–697
- 148 *Szliszka E, Czuba ZP, Mazur B, Sedek L, Paradysz A, Krol W.* Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells. *Int J Mol Sci* 2009; 11: 1–13
- 149 *Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MY, Darzynkiewicz Z, Wu JM.* Licochalcone-A, a novel flavonoid isolated from licorice root (*Glycyrrhiza glabra*), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. *Biochem Biophys Res Commun* 2004; 322: 263–270
- 150 *Lee CK, Son SH, Park KK, Park JHY, Lim SS, Kim SH, Chung WY.* Licochalcone A inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice. *Basic Clin Pharmacol Toxicol* 2008; 103: 48–54
- 151 *Yoon G, Kang BY, Cheon SH.* Topoisomerase I inhibition and cytotoxicity of licochalcones A and E from *Glycyrrhiza inflata*. *Arch Pharm Res* 2007; 30: 313–316
- 152 *Lee CS, Kwak SW, Kim YJ, Lee SA, Park ES, Myung SC, Kim W, Lee MS, Lee JJ.* Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways. *Eur J Pharmacol* 2012; 683: 54–62
- 153 *Szliszka E, Jaworska D, Ksek M, Czuba ZP, Król W.* Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells. *Int J Mol Sci* 2012; 13: 15343–15359
- 154 *Jiang J, Yuan X, Zhao H, Yan X, Sun X, Zheng Q.* Licochalcone A inhibiting proliferation of bladder cancer T24 cells by inducing reactive oxygen species production. *Biomed Mater Eng* 2014; 24: 1019–1025
- 155 *Yuan X, Li D, Zhao H, Jiang J, Wang P, Ma X, Sun X, Zheng Q.* Licochalcone A-induced human bladder cancer T24 cells apoptosis triggered by mitochondria dysfunction and endoplasmic reticulum stress. *Biomed Res Int* 2013; 2013: 474272
- 156 *Cho JJ, Chae JJ, Yoon G, Kim KH, Cho JH, Cho SS, Cho YS, Shim JH.* Licochalcone A, a natural chalconoid isolated from *Glycyrrhiza inflata* root, induces apoptosis via Sp1 and Sp1 regulatory proteins in oral squamous cell carcinoma. *Int J Oncol* 2014; 45: 667–674
- 157 *Hao W, Yuan X, Yu L, Gao C, Sun X, Wang D, Zheng Q.* Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways. *Sci Rep* 2015; 5: 1–8
- 158 *Kim JS, Park MR, Lee SY, Kim do K, Moon SM, Kim CS, Cho SS, Yoon G, Im HJ, You JS, Oh JS, Kim SG.* Licochalcone A induces apoptosis in KB human oral cancer cells via a caspase-dependent FasL signaling pathway. *Oncol Rep* 2014; 31: 755–762
- 159 *Park JH, Lim HJ, Lee KS, Lee S, Kwak HJ, Cha JH, Park HY.* Anti-proliferative effect of licochalcone A on vascular smooth muscle cells. *Biol Pharm Bull* 2008; 31: 1996–2000
- 160 *Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, Lambert G, DiPaola RS.* Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. *Anticancer Res* 1999; 20: 2653–2658
- 161 *Shen H, Zeng G, Tang G, Cai X, Bi L, Huang C, Yang Y.* Antimetastatic effects of licochalcone A on oral cancer via regulating metastasis-associated proteases. *Tumour Biol* 2014; 35: 1–8
- 162 *Kim YH, Shin EK, Kim DH, Lee HH, Park JHY, Kim JK.* Antiangiogenic effect of licochalcone A. *Biochem Pharmacol* 2010; 80: 1152–1159
- 163 *Kim YJ, Jung EB, Myung SC, Kim W, Lee CS.* Licochalcone A enhances geldanamycin-induced apoptosis through reactive oxygen species-mediated caspase activation. *Pharmacology* 2013; 92: 49–59
- 164 *Funakoshi-Tago M, Tago K, Nishizawa C, Takahashi K, Mashino T, Iwata S, Inoue H, Sonoda Y, Kasahara T.* Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation. *Biochem Pharmacol* 2008; 76: 1681–1693
- 165 *Kim JK, Shin EK, Park JH, Kim YH, Park JHY.* Antitumor and antimetastatic effects of licochalcone A in mouse models. *J Mol Med (Berl)* 2010; 88: 829–838
- 166 *Shibata S, Inoue H, Iwata S, Ma RD, Yu LJ, Ueyama H, Takayasu J, Hasegawa T, Tokuda H, Nishino A, Nishino H, Iwashima A.* Inhibitory effects of licochalcone A isolated from *Glycyrrhiza inflata* root on inflammatory ear edema and tumour promotion in mice. *Planta Med* 1991; 57: 221–224
- 167 *Yuan X, Li T, Xiao E, Zhao H, Li Y, Fu S, Gan L, Wang Z, Zheng Q.* Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis. *Food Chem Toxicol* 2014; 65: 242–251
- 168 *Chang HJ, Yoon G, Park JS, Kim MH, Baek MK, Kim NH, Shin BA, Ahn BW, Cheon SH, Jung YD.* Induction of apoptosis by the licochalcone E in endothelial cells via modulation of NF- κ B and Bcl-2 Family. *Biol Pharm Bull* 2007; 30: 2290–2293
- 169 *Kwon SJ, Park SY, Kwon GT, Lee KW, Kang YH, Choi MS, Yun JW, Jeon JH, Jun JG, Park JH.* Licochalcone E present in licorice suppresses lung metastasis in the 4T1 mammary orthotopic cancer model. *Cancer Prev Res* 2013; 6: 603–613
- 170 *Zhang SP, Zhou YJ, Liu Y, Cai YQ.* Effect of liquiritigenin, a flavanone existed from *Radix Glycyrrhizae* on pro-apoptotic in SMMC-7721 cells. *Food Chem Toxicol* 2009; 47: 693–701
- 171 *Liu C, Wang Y, Xie S, Zhou Y, Ren X, Li X, Cai Y.* Liquiritigenin induces mitochondria-mediated apoptosis via cytochrome c release and caspases activation in HeLa Cells. *Phytother Res* 2011; 25: 277–283
- 172 *Wang Y, Xie S, Liu C, Wu Y, Liu Y, Cai Y.* Inhibitory effect of liquiritigenin on migration via downregulation proMMP-2 and PI3K/Akt signaling pathway in human lung adenocarcinoma A549 cells. *Nutr Cancer* 2012; 64: 627–634
- 173 *Liu Y, Xie S, Wang Y, Luo K, Wang Y, Cai Y.* Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells. *Molecules* 2012; 17: 7206–7216
- 174 *Zhou M, Higo H, Cai Y.* Inhibition of hepatoma 22 tumor by liquiritigenin. *Phytother Res* 2010; 24: 827–833
- 175 *Huang W, Tang S, Qiao X, Ma W, Ji S, Wang K, Ye M, Yu S.* Isoangustone A induces apoptosis in SW480 human colorectal adenocarcinoma cells by disrupting mitochondrial functions. *Fitoterapia* 2014; 30: 36–47
- 176 *Lee E, Son JE, Byun S, Lee SJ, Kim YA, Liu K, Kim J, Lim SS, Park JH, Dong Z, Lee KW, Lee HJ.* CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth. *Toxicol Appl Pharmacol* 2013; 272: 12–20
- 177 *Song NR, Lee E, Byun S, Kim JE, Mottamal M, Park JH, Lim SS, Bode AM, Lee HJ, Lee KW, Dong Z.* Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3K, MKK4, and MKK7 in human melanoma. *Cancer Prev Res* 2013; 6: 1293–1303

- 178 Tsai YM, Yang CJ, Hsu YL, Wu LY, Tsai YC, Hung JY, Lien CT, Huang MS, Kuo PL. Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/Rho signaling pathway. *Integr Cancer Ther* 2011; 10: 341–349
- 179 Hsu YL, Wu LY, Hou MF, Tsai EM, Lee JN, Liang HL, Jong YJ, Hung CH, Kuo PL. Glabridin, an isoflavan from licorice root, inhibits migration, invasion and angiogenesis of MDA-MB-231 human breast adenocarcinoma cells by inhibiting focal adhesion kinase/Rho signaling pathway. *Mol Nutr Food Res* 2011; 55: 318–327
- 180 Hsieh MJ, Lin CW, Yang SF, Chen MK, Chiou HL. Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF-kappaB and AP-1 activity in human liver cancer cells. *Br J Pharmacol* 2014; 171: 3037–3050
- 181 Veratti E, Rossi T, Giudice S, Benassi L, Bertazzoni G, Morini D, Azzoni P, Bruni E, Giannetti A, Magnoni C. 18Beta-glycyrrhetic acid and glabridin prevent oxidative DNA fragmentation in UVB-irradiated human keratinocyte cultures. *Anticancer Res* 2011; 31: 2209–2215
- 182 Park SY, Lim SS, Kim JK, Kang IJ, Kim JS, Lee C, Kim J, Park JH. Hexane-ethanol extract of *Glycyrrhiza uralensis* containing licoricidin inhibits the metastatic capacity of DU145 human prostate cancer cells. *Br J Nutr* 2010; 104: 1272–1282
- 183 Zhou B, Zhang J, Wu S, Zhuo Q, Gao W, Hao J, Man S. The influence of compatibility of processed Radix Aconiti Kusnezoffii on the pharmacokinetic of four components in *Glycyrrhiza uralensis* Fisch. *J Ethnopharmacol* 2015; 169: 1–7
- 184 Lee YK, Chin YW, Bae JK, Seo JS, Choi YH. Pharmacokinetics of isoliquiritigenin and its metabolites in rats: low bioavailability is primarily due to the hepatic and intestinal metabolism. *Planta Med* 2013; 79: 1656–1665
- 185 Kang HE, Jung HY, Cho YK, Kim SH, Sohn SI, Baek SR, Lee MG. Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up. *J Pharm Sci* 2009; 98: 4327–4342
- 186 Wu YP, Meng XS, Bao YR, Wang S. Pharmacokinetic study of four flavones of *Glycyrrhiza* in rat plasma using HPLC-MS. *J Ethnopharmacol* 2013; 148: 266–270
- 187 Dudgeon DD, Shinde S, Hua Y, Shun TY, Lazo JS, Strock CJ, Giuliano KA, Taylor DL, Johnston PA, Johnston PA. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits. *J Biomol Screen* 2010; 15: 766–782
- 188 Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A, Hoheisel JD. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. *Biochem Pharmacol* 2009; 78: 273–283
- 189 Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J, Wang W. Potential anticancer activity of tanshinone IIA against human breast cancer. *Int J Cancer* 2005; 116: 799–807
- 190 Toledo-Sherman L, Deretey E, Slon-Usakiewicz JJ, Ng W, Dai JR, Foster JE, Redden PR, Uger MD, Liao LC, Pasternak A, Reid N. Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. *J Med Chem* 2005; 48: 3221–3230
- 191 Wang X, Zhang H, Chen L, Shan L, Fan G, Gao X. Licorice, a unique “guide drug” of traditional Chinese medicine: a review of its role in drug interactions. *J Ethnopharmacol* 2013; 150: 781–790
- 192 Lauren DR, Jensen DJ, Douglas JA, Follett JM. Efficient method for determining the glycyrrhizin content of fresh and dried roots, and root extracts, of *Glycyrrhiza* species. *Phytochem Anal* 2001; 12: 332–335
- 193 Pang X, Zhang L, Wu Y, Lin L, Li J, Qu W, Safe S, Liu M. Methyl 2-cyano-3, 11-dioxo-18-olean-1, 12-dien-30-oate (CDODA-Me), a derivative of glycyrrhetic acid, functions as a potent angiogenesis inhibitor. *J Pharmacol Exp Ther* 2010; 335: 172–179
- 194 Logashenko EB, Salomatina OV, Markov A, Korchagina DV, Salakhutdinov NF, Tolstikov GA, Vlassov VV, Zenkova MA. Synthesis and pro-apoptotic activity of novel glycyrrhetic acid derivatives. *Chembiochem* 2011; 12: 784–794
- 195 Salomatina OV, Markov AV, Logashenko EB, Korchagina DV, Zenkova MA, Salakhutdinov NF, Vlassov VV, Tolstikov GA. Synthesis of novel 2-cyano substituted glycyrrhetic acid derivatives as inhibitors of cancer cells growth and NO production in LPS-activated J-774 cells. *Bioorg Med Chem* 2014; 22: 585–593